<SEC-DOCUMENT>0001193125-22-255498.txt : 20220930
<SEC-HEADER>0001193125-22-255498.hdr.sgml : 20220930
<ACCEPTANCE-DATETIME>20220930160833
ACCESSION NUMBER:		0001193125-22-255498
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20220930
DATE AS OF CHANGE:		20220930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Solid Biosciences Inc.
		CENTRAL INDEX KEY:			0001707502
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				900943402
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38360
		FILM NUMBER:		221284124

	BUSINESS ADDRESS:	
		STREET 1:		500 RUTHERFORD AVENUE
		STREET 2:		3RD FLOOR
		CITY:			CHARLESTOWN
		STATE:			MA
		ZIP:			02129
		BUSINESS PHONE:		617-337-4680

	MAIL ADDRESS:	
		STREET 1:		500 RUTHERFORD AVENUE
		STREET 2:		3RD FLOOR
		CITY:			CHARLESTOWN
		STATE:			MA
		ZIP:			02129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Solid Biosciences, LLC
		DATE OF NAME CHANGE:	20170524
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d391920ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549</B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM
8-K</B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section 13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): September 30, 2022 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Solid Biosciences Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter)</B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-38360</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>90-0943402</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>500 Rutherford Avenue, Third Floor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Charlestown, Massachusetts 02129</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (617) 337-4680 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report)</B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see</I> General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock $0.001 par value per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SLDB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Global Select Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Emerging growth company &#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, on September&nbsp;29, 2022, Solid Biosciences Inc. (the &#147;Company&#148;) entered into an Agreement and Plan of Merger (the
&#147;Merger Agreement&#148;) by and among the Company, Greenland Merger Sub LLC, a Delaware limited liability corporation and a wholly owned subsidiary of the Company (&#147;Transitory Subsidiary&#148;), AavantiBio, Inc., a Delaware corporation
(&#147;AavantiBio&#148;), and, solely in his capacity as equityholder representative, Doug Swirsky. The Merger Agreement provides for the acquisition of AavantiBio by the Company through the merger of Transitory Subsidiary into AavantiBio, with
AavantiBio surviving as a wholly owned subsidiary of the Company (the &#147;Merger&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, on September&nbsp;29, 2022, the
Company entered into securities purchase agreements with several accredited investors (the &#147;Investors&#148;), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 159,574,463 shares of
the Company&#146;s common stock, at a price of $0.47 per share (the &#147;Private Placement&#148;), which is expected to close immediately following the closing of the Merger, subject to the satisfaction of specified customary closing conditions,
including approval from the stockholders of the Company, and contingent upon, among other things, the closing of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2022,
the Company and AavantiBio hosted a webcast presentation regarding the Merger between the Company and AavantiBio and the Private Placement (the &#147;Presentation&#148;). A&nbsp;transcript of the Presentation is furnished as Exhibit&nbsp;99.1 to
this Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> and is incorporated herein by reference, and a copy of the investor presentation was previously furnished as Exhibit&nbsp;99.2 to that certain Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed by the Company on September&nbsp;30, 2022, and which is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furnished
as Exhibit 99.2 to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and incorporated herein by reference are social media posts posted by the Company on Twitter and LinkedIn on September&nbsp;30, 2022 regarding the
announcement of the Merger and the Private Placement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished in this Item&nbsp;7.01 and Exhibits&nbsp;99.1 and 99.2 attached hereto
shall not be deemed to be &#147;filed&#148; for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of such section, nor shall such information be
deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;contains</FONT> &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations,
plans and prospects for the Company, AavantiBio and the combined company following the anticipated consummation of the proposed Merger; the anticipated benefits of the Merger; the anticipated timing of the Merger and Private Placement; the
anticipated milestones, business focus and pipeline of the combined company; the expected cash and cash investments of the combined company at closing of the transactions and the cash runway of the combined company; the excepted management team and
Board of the combined company; the <FONT STYLE="white-space:nowrap">Company&#146;s&nbsp;SGT-003&nbsp;program,</FONT> including expectations for filing an investigational new drug application and initiating dosing;
<FONT STYLE="white-space:nowrap">AavantiBio&#146;s&nbsp;AVB-202&nbsp;program</FONT> <FONT STYLE="white-space:nowrap">and&nbsp;AVB-401&nbsp;program,</FONT> including expectations for filing an IND
<FONT STYLE="white-space:nowrap">for&nbsp;AVB-202,&nbsp;and</FONT> other statements containing the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;would,&#148; &#147;working&#148; and similar expressions. Any forward-looking
statements are based on management&#146;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such
forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with: completion of the proposed Merger and Private Placement in a timely manner or on the anticipated terms or at all; the
satisfaction (or waiver) of closing conditions to the consummation of the merger and the private placement, including with respect to the approval of the Company&#146;s stockholders; the occurrence of any event, change or other circumstance or
condition that could give rise to the termination of the Merger Agreement or the Private Placement; the effect of the announcement or pendency of the Merger on the Company&#146;s or AavantiBio&#146;s business relationships, operating results and
business generally; the ability to recognize the anticipated benefits of the Merger; the outcome of any legal proceedings that may be instituted against the Company or AavantiBio following any announcement of the Merger and related transactions; the
ability to obtain or maintain the listing of the common stock of the combined company on the Nasdaq Stock Market following the Merger; risks related to the Company&#146;s and AavantiBio&#146;s ability to estimate their respective operating expenses
and expenses associated with the transaction, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and
costs that could reduce the combined company&#146;s cash resources; costs related to the Merger, including unexpected costs, charges or expenses resulting from the Merger; changes in applicable laws or regulation; the possibility that the Company or
AavantiBio may be adversely affected by other economic, business and/or competitive factors; competitive responses to the Merger and Private Placement; risks related to the Company&#146;s continued listing on the Nasdaq Global Select Market,
including the Company&#146;s ability to regain compliance with Nasdaq&#146;s minimum bid price requirement; the Company&#146;s ability to advance <FONT STYLE="white-space:nowrap">its&nbsp;SGT-003&nbsp;program</FONT> on the timelines expected or at
all, obtain and maintain necessary </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approvals from the U.S. Food and Drug Administration (&#147;FDA&#148;) and other regulatory authorities; following the Merger, the Company&#146;s ability to advance the programs acquired from
AavantiBio, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;AVB-202&nbsp;and&nbsp;AVB-401&nbsp;programs,</FONT></FONT> on the timelines expected or at all, obtain and maintain necessary approvals from the FDA and
other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring board; replicating in clinical trials positive results found in
preclinical studies and early-stage clinical trials of product candidates; whether the methodologies, assumptions and applications utilized to assess particular safety or efficacy parameters will yield meaningful statistical results; advancing the
development of product candidates under the timelines it anticipates in current and future clinical trials; successfully transitioning, optimizing and scaling the Company&#146;s manufacturing process; obtaining, maintaining or protecting
intellectual property rights related to the Company&#146;s and AavantiBio&#146;s product candidates; competing successfully with other companies that are seeking to develop Duchenne treatments, Friedreich&#146;s ataxia, BAG3 and other gene
therapies; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;SGT-003,&nbsp;AVB-202,&nbsp;AVB-401&nbsp;and</FONT></FONT></FONT> other product candidates; achieving the Company&#146;s other business
objectives and continuing as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company&#146;s actual results to differ from those contained in the forward-looking
statements, see the &#147;Risk Factors&#148; section, as well as discussions of potential risks, uncertainties and other important factors, in the Company&#146;s most recent filings with the SEC. In addition, the forward-looking statements included
in this Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;represent</FONT> the Company&#146;s views as of the date hereof and should not be relied upon as representing the Company&#146;s views as of any date subsequent to the
date hereof. The Company anticipates that subsequent events and developments will cause the Company&#146;s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;is</FONT> not a proxy statement or solicitation of a proxy, consent or authorization
with respect to any securities or in respect of the proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of securities in any state or jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information Will Be Filed with the SEC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Merger and the Private Placement, the Company intends to file with the SEC preliminary and definitive proxy statements relating to the
Merger and the Private Placement and other relevant documents. The definitive proxy statement will be mailed to the Company&#146;s stockholders as of a record date to be established for voting on the shares to be issued in the Merger and the Private
Placement and any other matters to be voted on at the special meeting. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS, ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY
OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE MERGER OR THE PRIVATE PLACEMENT OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY,
AAVANTIBIO, THE MERGER AND THE PRIVATE PLACEMENT. Investors and security holders may obtain free copies of these documents (when they become available) on the SEC&#146;s website at www.sec.gov, on the Company&#146;s website
at&nbsp;<U>www.solidbio.com</U>&nbsp;or by contacting the Company&#146;s Investor Relations via email at clowie@solidbio.com or by telephone <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at&nbsp;607-423-3219.</FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, AavantiBio
and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of the Company in connection with the issuance of shares in the Merger and Private Placement and any other matters
to be voted on at the special meeting. Information about the Company&#146;s directors and executive officers is included in the Company&#146;s most recent definitive proxy statement filed with the SEC on April&nbsp;28, 2022. Additional information
regarding the names, affiliations and interests of the Company&#146;s and AavantiBio&#146;s directors and executive officers will be included in the preliminary and definitive proxy statements (when filed with the SEC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These documents (when filed with the SEC) will be available free of charge as described above. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <I>Exhibits</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit<BR>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Transcript of Webcast Presentation held by Solid Biosciences Inc. and AavantiBio, Inc. on September&nbsp;30, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Social Media Posts posted by Solid Biosciences Inc. on September&nbsp;30, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cover Page Interactive Data File (formatted as Inline XBRL)</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>SOLID BIOSCIENCES&nbsp;INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: September&nbsp;30, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ilan Ganot</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Ilan Ganot</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:
&nbsp;&nbsp;Chief Executive Officer</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Solid Biosciences </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Business Update Call </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Presenters </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Caitlin Lowie - VP, Communications and IR, Solid Biosciences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ilan Ganot - <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> President and CEO, Solid Biosciences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bo Cumbo - President, Chief Executive Officer of AavantiBio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carl Morris - Chief Financial Officer, Solid Biosciences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jenny Marlow - Chief Scientific Officer, AavantiBio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve DiPalma - Interim Chief Financial Officer, Solid Biosciences </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Q&amp;A Participants </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst -
SVB Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst - Jefferies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst - Barclays </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Allison Bratzel -
Piper Sandler </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst - J.P. Morgan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst - Chardan </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and gentlemen, thank you for standing by and welcome to today&#146;s joint conference call with Solid Biosciences and AavantiBio to discuss their
strategic business transaction. Please be advised that today&#146;s conference may be recorded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I would now like to hand the conference over to Caitlin
Lowie, Vice President of Communications and Investor Relations at Solid Biosciences. Ms.&nbsp;Lowie, you may begin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Caitlin Lowie </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Good morning, and thank you, operator. Before we begin, I would like to remind everyone that this discussion and the accompanying presentation will contain
forward-looking statements based on the current expectations of Solid Biosciences and AavantiBio, including but not limited to statements regarding the expected timing, completion, effects, and potential benefits of the proposed merger and private
placement of our future expectation plan and prospects for the combined company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such statements represent management&#146;s judgment and intention as of
today, and involve assumptions, risks, and uncertainties. Actual results could differ material - materially from those discussed in these forward-looking statements due to a number of important factors, risks, and uncertainties, including those
risks set forth on slide two of the accompanying presentation and other risks described in the risk factors section of our most recently filed annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and other periodic reports filed with
the SEC. Solid and AavantiBio undertake no obligation to update any forward-looking statements after the date of this call. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>1</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, as indicated on slide three of the accompanying presentation, Solid Biosciences intends to file a
preliminary and definitive proxy statement with the SEC relating to the proposed merger and private placement. Please be advised to read, when available, the preliminary and definitive proxy statements and the other relevant documents filed with the
SEC, as these will contain important information about Solid, AavantiBio, and the transaction. Once available, these documents can be obtained free of charge from the SEC at SEC.gov or on the Solid Biosciences website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With me on today on the call are Ilan Ganot, <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> President, and Chief Executive Officer of Solid Biosciences;
Bo Cumbo, President and Chief Executive Officer of AavantiBio; Steve DiPalma, Solid&#146;s interim Chief Financial Officer; Dr.&nbsp;Carl Morris, Solid&#146;s Chief Financial Officer; and Dr.&nbsp;Jenny Marlow, Chief Scientific Officer for
AavantiBio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During today&#146;s call, we will share details of the strategic update the company announced this morning. Yesterday, Solid entered into a
definitive merger agreement to acquire AavantiBio, a privately held gene therapy company. Solid also entered into a securities purchase agreement with a select group of healthcare and biotech investors for a $75&nbsp;million private placement that
is expected to close concurrently with the closing of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will begin with opening remarks from Ilan, who will share details of the planned
acquisition of AavantiBio, followed by Bo, who will discuss Solid&#146;s strategic path forward. We will then open the call to questions. Before I turn the call over to Ilan, I want to acknowledge that the materials related to these transactions
were filed with the SEC this morning. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I&#146;d like to turn the call over to Solid&#146;s CEO, Ilan Ganot. Ilan? </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ilan Ganot </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thanks, Caitlin, and thank you all for
joining us this morning. When we founded Solid nearly 10 years ago, we wanted to identify a meaningful treatment&#151;meaningful treatment options for the boys and families who live with the devastating consequences of Duchenne muscular dystrophy.
Over that time, Solid has experienced many ups and downs, but our commitment to patients and our mission has remained our guide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I personally have had
the privilege of watching great science be conducted by our team, and the lives of boys who have been treated with our product candidate in clinical trials be improved. As the leadership team, the board and I have discussed how to position Solid for
success in the future and ensure that our treatment can reach patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>2</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognized a number of challenges that we were continually facing. One, manufacturing is a critical
factor in the development process. Two, a single disease focus with a single asset exposed us to greater market volatility and risk. Three, Solid has produced some interesting and innovative technologies, but was not able to explore their potential
with patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April, we began to address the first challenge when we announced our intention to focus our manufacturing on a single manufacturing
methodology, transient transfection, because we believed it would improve our consistency of supply as well as potentially improve the quality of the product candidate. That decision has thus far proven to be a positive one. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Today&#146;s announcement of the proposed merger and private placement I believe will help address the last two challenges. We believe that diversifying
Solid&#146;s business into more disease areas will allow us to open doors to new investment and create a more stable business model to move our Duchenne program to patients. AavantiBio emerged as an ideal partner, and a group of healthcare and
biotech investors agreed to commit $75&nbsp;million in a PIPE that was announced alongside the acquisition of AavantiBio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First, a bit about the
transactions before I hand it over to Bo Cumbo, who will assume the role of President and CEO of Solid upon the closing of the transactions. The acquisition of AavantiBio is expected to strengthen and expand Solid&#146;s pipeline and add
organizational capacity to help advance our programs into and through commercialization, and hopefully ultimately to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AavantiBio has been
developing a gene transfer product candidate for Friedreich&#146;s ataxia, or FA, another neuromuscular disease, as well as a <FONT STYLE="white-space:nowrap">product--as</FONT> well as product candidates for cardiac indications, including
BAG3-mediated dilated cardiomyopathy. Together, we believe that Solid has the potential to become a leader in gene therapy for neuromuscular and cardiac diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When discussions began to with Bo and the AavantiBio team, it was clear on that <FONT STYLE="white-space:nowrap">their--it</FONT> was clear that&#151;sorry,
it was clear early on that there were some natural synergies. First, AavantiBio has some great talent that would complement the leadership team we have here Solid. As you will see, the new team has strong leaders in all areas of the organization.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Second, the companies have similar pipelines. Obviously, Solid is focused on Duchenne, a neuromuscular disorder that has cardiac manifestations. There
are many similarities between Duchenne, Friedreich&#146;s ataxia, and the cardiac programs that AavantiBio is developing. We&#146;re also both working to identify promising next generation novel capsids. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, both companies have found themselves in a similar place with manufacturing. Just as we have begun to focus on transient transfection-based
manufacturing in our manufacturing platform, AavantiBio has made a similar decision to switch from HSV to transient transfection. We believe we can drive consistent drug product with desired quality attributes by having a single specialized CMC team
working across these programs. All of these activities will support our goal of having multiple programs in the clinic in the coming years, leading with <FONT STYLE="white-space:nowrap">SGT-003</FONT> for Duchenne. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>3</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, few details on the transactions we announced in the press release earlier this morning. Solid signed a
definitive agreement to acquire AavantiBio concurrently with a $75&nbsp;million private placement in Solid. The private placement will add to the combination of existing cash from both Solid and Aavanti. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger is an all stock transaction where, upon closing, AavantiBio shareholders will own approximately 15% of the combined company. Upon the closing, the
combined company will operate as Solid Biosciences under the ticker SLDB, and AavantiBio will become a wholly-owned subsidiary of Solid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger has
been approved by the boards of Solid and AavantiBio, as well as stockholders of AavantiBio. We expect the merger to close by the end of this year, subject to approval of Solid stockholders and other customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $75&nbsp;million PIPE will close concurrently with the acquisition of AavantiBio. In the PIPE, we agreed to sell approximately 159&nbsp;million shares of
common stock at $0.47 per share. Our lead investors in the PIPE are Perceptive Advisors, RA Capital Management, and Bain Capital Life Sciences. Other new and existing investors include CaaS Capital Management, Invus, Laurion Capital Management, and
Pura Vida Investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, we expect the combined company to have cash and investments of approximately $215&nbsp;million at close, which we expect
will be sufficient to fund operations and capital expenditures into 2025 and through important milestones for the lead programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With that, I am going to
hand it over to Bo Cumbo. I have known Bo for nearly 10 years now. I&#146;ve also worked closely with Bo recently as we have discussed how to bring these two organizations together. Through that process, we discussed the future leadership of the
company as I was thinking about my next phase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bo has significant experience bringing products through development and commercialization, and I believe
he is a strong leader for this next phase of Solid. I look forward to working with Bo in the future, both as a member of Solid&#146;s Board of Directors and as a strategic business advisor during this transition period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bo Cumbo </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thanks, Ilan. I&#146;m really glad to join you
today. While I&#146;ve been out of DMD for multiple years and had not anticipated coming back into the Duchenne space, I&#146;m truly excited to help the children, young men, and their extended families suffering from the consequences of Duchenne. I
care deeply for this patient community, and I hope that Solid, as well as the entire industry trying to make advancements in care for patients suffering from DMD, find success and change the course of this disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>4</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With that said, I have a vision of building a company that will tackle additional severe genetic diseases,
and we hope to be a leader in developing novel therapies in both the neuromuscular and cardiac spaces. Over the next few slides, I will walk you through what we envision the future of the company will become and what we expect to happen in the next
couple years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Ilan mentioned, the core of the company will be built upon three pillars; people, pipeline, and process. And I&#146;m going to walk
through each of those, but first a bit about the combined company. We will be headquartered in Charlestown, Massachusetts under Solid&#146;s roof. They have great R&amp;D and analytical and process development labs. We also will leverage
Aavanti&#146;s Vector Core, located in North Carolina, that can produce material for small-scale studies while our PD teams can stay very focused on our lead programs. We value AavantiBio&#146;s current relationship with the University of Florida,
and we intend to maintain a research presence in Gainesville. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Ilan noted, this merger would significantly diversify Solid&#146;s pipeline. All of the
programs in the combined company&#146;s pipeline focus on rare diseases that are estimated to have greater than 5,000 treatable patients in the United States alone. As we look out over the next few years of the combined company, we have some key
anticipated milestones we aim to achieve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First, we expect to close the transaction by the end of this year following a Solid shareholder vote. In <FONT
STYLE="white-space:nowrap">mid-2023,</FONT> we anticipate an IND submission for <FONT STYLE="white-space:nowrap">SGT-003.</FONT> You probably saw in the press release that <FONT STYLE="white-space:nowrap">SGT-003</FONT> has been prioritized over
Solid&#146;s first generation program, <FONT STYLE="white-space:nowrap">SGT-001,</FONT> which will be paused. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will get into that in a minute, but
after having lengthy discussion with Solid&#146;s leadership team these past few weeks, I&#146;m very supportive of their decision to make <FONT STYLE="white-space:nowrap">SGT-003</FONT> the primary focus of the company&#146;s Duchenne efforts
moving forward. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the second half of 2024, we anticipate submitting an IND for our other lead program,
<FONT STYLE="white-space:nowrap">AVB-202,</FONT> for the treatment of Friedreich&#146;s ataxia. This is a neuromuscular disorder that has neurological as well as cardiac manifestations affecting muscle control and coordination, with possible loss of
vision, hearing, and slurred speech. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also plan to initiate IND enabling activities for <FONT STYLE="white-space:nowrap">AVB-401</FONT> for the
treatment of BAG3-mediated dilated cardiomyopathy, or BAG3, in 2024. BAG3 is a devastating disease that can ultimately lead to halt&#151;heart failure. We also plan to continue our effort to develop novel AV cardiac directed capsids for our emerging
cardiac pipeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We&#146;re excited to highlight the executive team post merger. This group has extensive experience in genetic medicine and will be a
major asset to the combined company as we move forward. After the closing of the merger, I will assume the role as the president and CEO. I&#146;ve been in the industry for 28 years in specialty or rare disease companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>5</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the past two years, I&#146;ve been solely focused on building AavantiBio, and am extremely proud of the
exciting work we have done. Before Aavanti, I was at Sarepta Therapeutics for eight years, where I served as the Executive Vice President and Chief Commercial Officer. Prior to that, I worked at both Vertex and Gilead. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The scientific foundation of the combined company is on the call today, Dr.&nbsp;Morris and Dr.&nbsp;Marlowe. Carl will be our Chief Scientific Officer for
neuromuscular programs. He is a muscle biologist by training and has been in the industry for very long time. Prior to Solid, Carl worked at Pfizer. Carl is well known in the neuromuscular space, and I&#146;ve known him for an extended period of
time. I&#146;m very grateful that Carl and I get to work together. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jenny is currently the scientific officer&#151;Chief Scientific Officer at Aavanti.
She will be the CSO responsible for our Friedreich&#146;s ataxia and cardiac programs. Prior to joining Aavanti, Jenny was the vice president of preclinical and translational development for bluebird bio. Jenny also spent 11 years in the
Novartis&#146; preclinical safety group and is a molecular toxicologist by training. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So, we have a muscle biologist and a toxicologist, which will really
sync up nicely for the work we need to accomplish. Carl and Jenny will combine efforts and continue the work on our capsid libraries for both skeletal and cardiac tissues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is important to have regulatory expertise on the executive team, and we will have one of the best in the industry with Dr.&nbsp;Jessie Hanrahan. Jessie is
well known globally and has worked with EMA, OTAT, and others. Jessie came to Aavanti from bluebird, where she was the vice president of regulatory. She&#146;s also been with Boston Scientific as well as Genzyme. Jessie <FONT
STYLE="white-space:nowrap">had--also</FONT> has an incredible team with experience in both regulatory strategy and CMC regulatory within gene and cell therapies. This team will help support all our efforts going forward. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paul Herzich will be the Chief Technology Officer. Paul has decades of experience right where you want it, in gene therapy and biologics. Prior to Aavanti,
Paul was the Vice President of CMC at BridgeBio. Prior to this, he was also at Novartis, LogicBio, Bamboo, etc., so he has deep gene therapy experience and is very well known within the CMC community. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Roxana Dreghici will be the head of clinical development. Roxana is a specialist within Duchenne and spinal muscular atrophy, and is very well known
within the industry and Duchenne community. She was at Roche prior to Solid, and I&#146;m very excited to have <FONT STYLE="white-space:nowrap">her--have</FONT> the opportunity to work with Roxana. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>6</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steve DiPalma, who&#146;s on the call today, has extensive experience as a CFO in the biotech and pharma
space, and has been the interim CFO at Solid for the past couple years. He will stay with us while we recruit an experienced CFO in the Boston area. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ty
Howton rounds out the team as the Chief Administrative Officer. Ty currently serves as AavantiBio&#146;s Chief Operating Officer and will oversee legal, HR, and program management, among other functions. Ty has been on the executive teams of Vertex,
Sarepta, and Aavanti. His background is in law. And while he will <FONT STYLE="white-space:nowrap">head--be</FONT> the head of legal, he also brings the experiences he&#146;s gained in 20 plus years at companies like Aavanti, Sarepta, Vertex, and
Genentech in areas including regulatory, preclinical, CMC, government affairs, and patient advocacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This merger will also bring together all the pieces
you need to be a leading genetic medicine company. We have the vector core up and running, as well as animal models and supporting natural history studies in place within the key diseases, and great scientists able to develop novel capsids,
regulatory elements, and promoters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger is also expected to bring together a network of research partners globally that will help support our
ongoing research efforts for our pipeline programs. We believe this merger will put all the critical pieces together to create a leading gene therapy company, and our goal is to have multiple INDs in the coming years, leading with our next
generation microdystrophin program, <FONT STYLE="white-space:nowrap">SGT-003,</FONT> followed by <FONT STYLE="white-space:nowrap">AVB-202</FONT> for FA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This will be the company&#151;combined company&#146;s initial pipeline, bringing together gene therapy candidates from Solid and Aavanti. I&#146;m very
excited about the combined pipeline. As you can see, we are targeting an IND submission for our lead program, <FONT STYLE="white-space:nowrap">SGT-003,</FONT> in mid 2023, with patient dosing starting in late 2023, pending IND acceptance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">AVB-202</FONT> for FA will follow that, with an anticipated IND submission in the second half of &#145;24. <FONT
STYLE="white-space:nowrap">AVB-401</FONT> for BAG3 is currently in preclinical development, and hopefully in the future we will be in a position to share details on our undisclosed cardiac targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I think everyone on this call knows Duchenne and how devastating this disease is and can be to patients and families. You also know that Solid has potentially
the best in class microdystrophin construct containing the nNOS binding domain. I will spend a few moments on the announcement that Solid made this morning regarding <FONT STYLE="white-space:nowrap">SGT-003,</FONT> notably to pause <FONT
STYLE="white-space:nowrap">SGT-001</FONT> and prioritize <FONT STYLE="white-space:nowrap">SGT-003</FONT> as the lead Duchenne program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This slide shows
the evolution of Solid&#146;s microdystrophin programs, starting with <FONT STYLE="white-space:nowrap">SGT-001,</FONT> which was used in the IGNITE DMD study, to the second-generation <FONT STYLE="white-space:nowrap">SGT-001</FONT> manufactured
using a triple transfection process, and finally Solid&#146;s next generation program on the right-hand side, <FONT STYLE="white-space:nowrap">SGT-003,</FONT> which will be the leading&#151;lead going forward. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>7 of 18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As you know, <FONT STYLE="white-space:nowrap">SGT-003</FONT> delivers Solid&#146;s nNOS microdystrophin
protein with a novel capsid. Using a reporter transgene, this capsid has shown a 10 times improvement in transgene expression compared to AAV9, a two times increase in muscle distribution compared to AAV9, and it&#146;s liver <FONT
STYLE="white-space:nowrap">de-targeting,</FONT> showing less than half the biodistribution to the liver compared to AAV9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that <FONT
STYLE="white-space:nowrap">SGT-003</FONT> could be best in class and offer improved microdystrophin expression at lower viral loads. Solid has been delivering <FONT STYLE="white-space:nowrap">SGT-003</FONT> since the program was publicly launched in
May of last year, including conducting nonhuman primate study, <FONT STYLE="white-space:nowrap">scale-up</FONT> activities at the CDMO partner, and several confirmatory nonclinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This slide shows some of the data that Solid has previously shared that demonstrated the benefit of novel capsid. Ultimately, the team decided that <FONT
STYLE="white-space:nowrap">SGT-003</FONT> now deserves the focus of Solid&#146;s Duchenne efforts in order to achieve the timeline we have set, and anticipate IND submission in mid 2023 and subject to IND clearance, patient dosing, and anticipated
in late 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Over the next few months, we will complete current ongoing preclinical and manufacturing activities for
<FONT STYLE="white-space:nowrap">SGT-001.</FONT> This will allow us to pause <FONT STYLE="white-space:nowrap">SGT-001</FONT> when it&#146;s ready for IND filing. I&#146;m spending time on this because I know many people have asked the Solid team
about the two DMD programs and at what point they would go to a single program. I fully support the decision management <FONT STYLE="white-space:nowrap">made--has</FONT> made to prioritize and progress <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SG--and</FONT></FONT> progress <FONT STYLE="white-space:nowrap">SGT-003.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we&#146;ve mentioned a few times, we expect
to bring <FONT STYLE="white-space:nowrap">SGT-003</FONT> to patients in a clinical setting next year, pending an IND acceptance. Our immediate focus in the coming months will being able to complete our manufacturing and regulatory engagement
activities to support our anticipated IND submission next year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, our second program is going to be <FONT STYLE="white-space:nowrap">AVB-202</FONT>
for the treatment of Friedreich&#146;s ataxia. FA is similar to Duchenne in that it&#146;s caused by a lack of a protein, frataxin. It&#146;s a multisystem disease that has both neurological and cardiac manifestations that can be severe. We plan to
address the cardiac and neuromuscular manifestations, administering <FONT STYLE="white-space:nowrap">AVB-202</FONT> via both intrathecal and intravenous routes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">What is important about FA is that it&#146;s not just the amount of frataxin that is required, but it&#146;s the distribution of frataxin to the targeted
locations throughout the relevant target tissues of the central nervous system as well as the heart. Aavanti&#146;s frataxin transgene fits very nicely within the capsid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is full-length human frataxin with the addition of regulatory elements that are naturally occurring in the 3&#146; UTR region. We are using the CBA
promoter as well as AV9, and I will show you the iterations on how our program has evolved to what we believe has the potential to be the best in class gene therapy for the treatment of FA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>8</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to what Solid did, we took multiple iterations and reviewed every aspect of our product candidate to
make a potentially best in class program, <FONT STYLE="white-space:nowrap">AVB-202.</FONT> Whether it was codon optimizing the gene, the manufacturing platform in which we moved away from HSV to transient transfection, adding in regulatory elements,
and then AV9 with a plasma design that is optimize for yield and productivity, we have ended up with an optimized construct and delivery, which is shown of this right-hand side slide. We will use this construct to advance IND enabling activities and
manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> using a transient transfection process to support an anticipated IND submission in the second half of 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Here is some of the preclinical data for <FONT STYLE="white-space:nowrap">AVB-202</FONT> we have collected. This model is a frataxin deficient knockout mouse
model. We&#146;ve performed experiments in this mouse model in both <FONT STYLE="white-space:nowrap">pre-</FONT> and post-symptomatic contexts to understand whether we could change the course of the disease after symptom onset or before, and
we&#146;re very pleased with the results in both models, in which we observed that <FONT STYLE="white-space:nowrap">AVB-202</FONT> extended survival and improved cardiac function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also understand from the preclinical studies that frataxin is functional in the dosed mouse mitochondria, because you can look at the health of the
mitochondria through the surrogate marker called succinate dehydrogenase, which we see return to normal levels post-dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, our third program is going
to be <FONT STYLE="white-space:nowrap">AVB-401</FONT> for the treatment of BAG3-mediated dilated cardiomyopathy, or BAG3. The BAG3 gene codes for this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCL-2-associated</FONT></FONT>
athanogene 3 protein, or BAG3. If you don&#146;t have BAG3 protein or a reduction in the BAG3 protein, you are likely to end up with dilated cardiomyopathy and ultimately heart failure. If you have this disease, you are likely going to seek
treatment because your daily activities are severely impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are using rh74 to deliver an optimized BAG3 transgene with a specific cardiac promoter,
and we are piggybacking off FA and Duchenne with transient transfection manufacturing process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, there are a lot of synergies we expect to come
together with this transaction, including the next generation capsid libraries the two companies are independently developing. Aavanti was working on discovering next generation highly complex cardiac capsid libraries generated through a combination
of rational design and random mutagenesis, screened via directed evolution and nonhuman primates using an <FONT STYLE="white-space:nowrap">RNA-based</FONT> readout for positive selection from cardiac tissues and DNA for negative selection from liver
tissue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Meanwhile, Carl and the team at Solid were working on a <FONT STYLE="white-space:nowrap">ground-up</FONT> rational design approach to optimize
capsids and drive expression to skeletal muscle while lowering transduction to the liver. We expect the combination of the two developed programs to create large tissue specific capsid libraries that we believe we can leverage for our own internal
R&amp;D programs as well as potentially to <FONT STYLE="white-space:nowrap">out-license</FONT> for <FONT STYLE="white-space:nowrap">non-core</FONT> disease areas. Of note, on the bottom right of this slide, you can see the results from SLB101, the
capsid used in <FONT STYLE="white-space:nowrap">SGT-003.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>9</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, we believe that CMC is the foundation of the drug, and we will focus our efforts on having the best in
class CMC for all our programs. As I mentioned earlier, we have full teams, QA, QC, PD, AD, and great labs. We will also have CMC regulatory teams integrated in each one of our programs right from the beginning, so we always have an eye on CMC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This slide helps to illustrate why CMC is so important. I want you to look at just the first two columns because there is only one thing that has changed from
column one to column two. It&#146;s not the dose. It&#146;s not the capsid. It&#146;s not the transgene. It&#146;s the manufacturing process. Switching from an HSV to a transient transfection process increased the microdystrophin expression by
approximately 1.5 fold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, this is when column three comes into play. <FONT STYLE="white-space:nowrap">SGT-003,</FONT> using the novel capsid, showed
nearly a two times increase in microdystrophin expression when compared to <FONT STYLE="white-space:nowrap">SGT-001</FONT> when both product candidates are manufactured using transient transfection. The only thing that changed between column two and
three is using <FONT STYLE="white-space:nowrap">AAV-SLB101</FONT> capsid instead of AAV9. In summary, they observed two to three times better expression with <FONT STYLE="white-space:nowrap">SGT-003</FONT> using triple transfection compared to <FONT
STYLE="white-space:nowrap">SGT-001</FONT> using the HSV process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aavanti and Solid&#146;s respective manufacturing partners are currently in place for FA
and Duchenne. And as I mentioned before, Aavanti&#146;s vector core is able to support smaller scale needs for BAG3 and the other cardiac programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we turn to questions, I want to review some of the combined company key milestones we discussed during today&#146;s call. First, we expect to close the
merger by the end of the year, following a solid shareholder vote, including a $75&nbsp;million financing in connection with the business combination, providing a total cash position at the close of the transactions of approximately
$215&nbsp;million, which is expected to extend our runway into 2025 and through important key milestones for our lead programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Next, we plan to report
new data from the IGNITE DMD phase 1/2 clinical trial of our first generation program, <FONT STYLE="white-space:nowrap">SGT-001,</FONT> in <FONT STYLE="white-space:nowrap">the--early</FONT> 2023. This will include the study&#146;s preliminary report
of all patients to the primary endpoint of one year, as well as three year longitudinal data for the first three patients treated in the high-dose cohort. Again, we anticipate submitting an IND submission for
<FONT STYLE="white-space:nowrap">SGT-003</FONT> mid next year. And pending IND acceptance, we expect the dosing in late 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, we currently
expect to submit an IND for our FA program in the second half of 2024, which is subject to an IND clearance, will lead then to first patient dosing. In addition, we plan to move our BAG3 program into IND enabling studies, advance our early stage
cardiac programs, and continue development work on our capsids. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>10</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As you can see, I&#146;m very excited about the opportunities in front of us and hope to build a leading
gene therapy company in both neuromuscular and cardiac space. We have a talented team, a diversified pipeline we believe potentially could be best in class, and a strategic focus on a single manufacturing methodology. We also expect to have a strong
cash position that <FONT STYLE="white-space:nowrap">will--we</FONT> expect will be sufficient to achieve the milestones just discussed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And with that,
I&#146;ll turn it over to Ilan to close. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ilan Ganot </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you, Bo, and I also want to thank all the Solid and AavantiBio employees for their tireless efforts. You&#146;ve all done important work for patients,
and I look forward to seeing what these two teams can achieve together. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you all for dialing in. We can take some questions now. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you. If you&#146;d like to be placed in
the question queue, please press <FONT STYLE="white-space:nowrap">star-one</FONT> on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press <FONT STYLE="white-space:nowrap">star-two</FONT> if
you&#146;d like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing <FONT STYLE="white-space:nowrap">star-one.</FONT> One moment, please, while we poll for
questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our first question today is coming from Joe Schwartz from SVB Securities. Your line is now live. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hi. This is Beth on for Joe
Schwartz. Congrats, everyone, on this exciting advancement, and thanks for taking our question today. I was just curious if you could talk a little more about your decision to bring <FONT STYLE="white-space:nowrap">SGT-003</FONT> forward as your
lead pipeline candidate. Specifically curious how you&#146;re thinking about the opportunity for 003 in light of Sarepta&#146;s recent accelerated approval filing for their microdystrophin gene therapy, and, you know, any sort of learnings you can
take from 001 as you move 003 into clinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carl Morris </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yeah. Hi. Thanks. This is Carl Morris. Yeah, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">we--we&#146;ve</FONT></FONT> been going through <FONT
STYLE="white-space:nowrap">de-risking</FONT> of 003 all the way through, and so it got to a point where we were quite confident in where it&#146;s at. Also, we received some guidance from the FDA recently around
<FONT STYLE="white-space:nowrap">SGT-001</FONT> that sort of brought the timelines a little bit closer together, and really made the strategic decision to move forward with our next gen program, 003. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We&#146;ve gone through our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pre-IND--we&#146;ve</FONT></FONT></FONT> gone through the <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting. We also have scale up activities <FONT
STYLE="white-space:nowrap">with--at</FONT> our CDMO partner, Forge. So, we&#146;re in a good place to move forward with <FONT STYLE="white-space:nowrap">SGT-003</FONT> at this point in time, and really made that decision. And I&#146;ll pass over to
Bo to talk a little bit about the Sarepta. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>11</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bo Cumbo </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yeah. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">They&#146;ve--you</FONT></FONT> know, just regarding Sarepta, I think <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">they&#146;ve--one,</FONT></FONT> they&#146;ve made tremendous progress over the last couple years. And I think it&#146;s not only great for the industry, but also great for the children
suffering from DMD. We&#146;ll continue <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">to--you</FONT></FONT> know, they&#146;ve laid out a very clear path, and we should try to follow it. And <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">we&#146;ll--you</FONT></FONT> know, we&#146;ll move with lightning speed to try to get there with 003. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ilan Ganot </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yeah. I&#146;d just add that, you know, we&#146;ve always had this in mind because the protein is the same protein between 001 and 003. And we believe that
everything we&#146;re seeing in 001 should give us a lot of confidence to move 003 aggressively forward. Thank you for the question. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified
Analyst </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Great. Thanks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you. Our next question is coming from Maury Raycroft from Jeffries. Your line is now live. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hi. Good morning. This is Farsid
[ph] on for Maury. Congrats on the update and thanks for taking our question. To clarify, for 202 for FA, is there preclinical data in the slide deck? I&#146;m guessing that only they have been IV injected. Can you clarify that? And then can you
also talk about what you&#146;re seeing in the NHP data and more on how the dual IV/IT dosing would work? </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bo Cumbo </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yeah. I think what I&#146;m going to do is I&#146;m going to turn it over to Jenny in a second.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">We&#146;re--you</FONT></FONT> know, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">we--I</FONT></FONT> think <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">we--you</FONT></FONT> saw the preclinical data <FONT STYLE="white-space:nowrap">that--the</FONT> cardiac mouse model, and, you know, continuing to do additional work for IND enabling studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-human</FONT> primate data&#151;this is for FA, right? Yeah. For nonhuman primate data, it&#146;s continuing and
ongoing. We&#146;re going to have to do additional studies. As I mentioned, we are switching over from HSV manufacturing platform to triple transfection manufacturing platform, and there will be compatibility studies that we&#146;ll have to complete
as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jenny? </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jenny Marlow </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yeah. Thank you for your question. To answer directly the question around IV administration, yes, in that particular model we dosed IV only. In our nonhuman
primate model, we are dosing by the dual route of administration, both intravenous and by IT. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>12</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Got it. And then for the 202 optimization and plasmid design, how do you see a differentiation versus other competitors in development? </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bo Cumbo </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For 202, you know, I only know of really one
company that <FONT STYLE="white-space:nowrap">is--that&#146;s</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in--you</FONT></FONT> know, that&#146;s done preclinical work and made it all the way to IND, and that&#146;s
Lexeo. So, I&#146;m not exactly sure their construct design compared to ours. But we&#146;ve, you know, done a lot of work, as we mentioned on the slide, looking at codon optimization, adding in regulatory elements, moving to triple transfection.
So, you know, I think it&#146;s a little too early to compare. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">But we&#146;re very confident in our program. We&#146;ve done a lot of work over the last
couple years, and we&#146;re going to continue to do some more animal work. So, we&#146;re <FONT STYLE="white-space:nowrap">very--and</FONT> we understand exactly how this drug should react when we get to the IND. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Got it. Thank you so much. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you. Our next question is coming from
Gina Wang from Barclays. Your line is now live. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is Sheldon on for Gina. Thanks for taking our question. So, maybe first question is, could you remind us what are the remaining steps for the IND filing
for <FONT STYLE="white-space:nowrap">SGT-003?</FONT> And second question is I think you mentioned switching from HSV to the triple transfection was intended for when you initiate dosing with 001. So, could you give us some color on whether that
switching on the solid part right now is <FONT STYLE="white-space:nowrap">already--is</FONT> it already completed, and how would you coordinate the transition from HSV to transient for both organizations? Thanks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ilan Ganot </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I&#146;ll start just by saying that, you
know, Carl&#146;s going to mention some of the additional steps for the IND submission for 003. But as far as 001 goes, you know, we have nine patients who have been treated. We really like the data, and it continues to get collected on annual
visits. We&#146;re expecting three year functional outcomes coming soon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We&#146;re very excited about the durability profile of the treatment, and so we
will definitely expect to see that and more from 003. And as Carl mentioned, this was sort of like a process <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of--an</FONT></FONT> ongoing process of
<FONT STYLE="white-space:nowrap">de-risking,</FONT> you know, potentially the relapses coming to clinic. But as we learned more about 003, we learned more about the novel capsid. You know, we went from in vitro to in vivo, and then in vivo in HP
data, all in order to get comfortable for that to turn into our lead, effectively, today. But Carl can talk more about the specifics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>13</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carl Morris </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yeah. Just on the 001 program, we are continuing with some of the nonclinical work as well as some manufacturing work on the 001 program. So, if something does
delay or stop the 003 program, we will have that ready to go. So, we are continuing getting into a good pausing point. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <FONT
STYLE="white-space:nowrap">SGT-003</FONT> program, we&#146;ve completed it. We sort of have guidance from the FDA via the <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting. We are sort of in the midst of sort of working through the IND
enabling nonclinical work, and we have scaled up the manufacturing to a place where we can <FONT STYLE="white-space:nowrap">actually--to</FONT> a scale that can supply the clinical study. So, we&#146;re in the process of getting to the GMP and
finalizing all the study reports so we can submit the IND as soon as possible. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you so much. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you. Our next question is coming from Allison Bratzel from Piper Sandler. Your line is now live. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Allison Bratzel </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hi. Good morning. Congrats on all the
updates, and thanks for holding this call and for taking my question. Could you just walk us through what assumptions are included in your 2025 cash run rate guidance in some more detail, and also just walk us through the expected cadence of value
inflection points you&#146;re anticipating for <FONT STYLE="white-space:nowrap">SGT-003</FONT> and the <FONT STYLE="white-space:nowrap">AVB-202</FONT> through 2025? Does that contemplate clinical data is available for both assets by that 2025
timeframe? Thanks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bo Cumbo </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yeah. Let&#146;s kick
it over to Steve for the financial update. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve DiPalma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yeah. So, the runway would encompass important milestones in both programs. We do expect to have clinical readouts on 003, and also, you know, likely on 002
and FA as well into early 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bo Cumbo </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yeah. I
think just answer your question, I mean, we&#146;re going <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">to--you</FONT></FONT> know, some of the milestones that we&#146;ll have from inflection points in the next couple of years,
we&#146;ll obviously close the merger at the end of this year. As I mentioned before, we&#146;ll have an IND submission for the next generation <FONT STYLE="white-space:nowrap">SGT-003</FONT> mid next year. We intend to dose patients in that 003
program at the end of next year as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will, you know, start having patient data expected from that same program, 003, in 2024. And the IND from FA
would take hold late &#145;24, and then we would start dosing patients, you know, soon after, whether it&#146;s through the runway or not. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">So--and</FONT></FONT> then BAG3 will
continue to move forward with IND enabling studies. Our other two cardiac programs will continue to move forward. And our capsid libraries both on the skeletal side as well as the cardiac side will have nonhuman primate data readouts early 2024, and
that we can look to utilize those capsids for whether it&#146;s our cardiac&#151;internal cardiac programs or <FONT STYLE="white-space:nowrap">out-license</FONT> for <FONT STYLE="white-space:nowrap">non-dilutive</FONT> financing. Thank you. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>14</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you. Our next question is coming from Anupam Rama from J.P. Morgan. Your line is now live. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hi. Thank you. This is actually
Malcolm in for Anupam. Congrats on the updates today, and thank you for taking the question, just one quick one. What&#146;s kind of the [inaudible] in terms of target IND submission for 003? Thank you. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carl Morris </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sorry, you broke up a little bit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bo Cumbo </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We couldn&#146;t hear the question. You broke
up. Could you repeat it? </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sure.
What are the gating factors that we should be mindful of in terms of thinking about target IND submission for 003? </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carl Morris </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Really, it&#146;s just the completion and the readouts from the IND enabling nonclinical work. We <FONT STYLE="white-space:nowrap">have--we</FONT> know what we
need to do. We&#146;ve been told what the FDA is expecting, so we&#146;re just going through the execution of those studies right now. And <FONT STYLE="white-space:nowrap">the--additionally,</FONT> we just have to ensure that we can release our
material, our GMP material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And that&#146;s really it. We have sort of a protocol outline, and we&#146;re looking at start
<FONT STYLE="white-space:nowrap">up--starting</FONT> up the sites. So, I think everything&#146;s in place and on track for a <FONT STYLE="white-space:nowrap">mid-2023</FONT> IND. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Excellent. Thank you. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you. As a reminder, that <FONT
STYLE="white-space:nowrap">star-one</FONT> to be placed in the question queue. Our next question is coming from Geulah Livshits from Chardan. Your line is now live. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>15</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hi. Good morning. This is Chloe for Geulah. So, thanks for taking the question and congratulations on the transaction. So, our question is you had guided to a
sort of cadence of news coming from the 001 program for later this year. And you were going to update <FONT STYLE="white-space:nowrap">on--have</FONT> a one year update on patients seven to nine and a potentially longer term update on the patients
treated with 001 later this year. We&#146;re wondering if that was still going to be the case. And a second question on enrollment in the IGNITE DMD study. Based on conversations with regulators so far, what is your idea of how many more patients
you&#146;ll need to dose before having a productive conversation with the FDA on any of this? </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carl Morris </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So, for the first part, yes, we will be communicating the primary endpoint data, the 12 month endpoint data from the IGNITE DMD study, as well as three year
data from a subset. And that should come out, you know, to <FONT STYLE="white-space:nowrap">the--later</FONT> this year or early next year, Q1 next year, as we had guided to. So, that hasn&#146;t changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are&#151;we&#146;re sort of communicating now that we&#146;re pausing the 001 program. And given that we needed to file a new IND for the 001, it&#146;s
unlikely we&#146;ll be sort of continuing with the dosing with 001 at this point. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unidentified Analyst </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All right. Thank you. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you. We have reached the end of our question and answer session. And ladies and gentlemen, that does conclude today&#146;s teleconference and webcast.
You may disconnect your lines at this time and have a wonderful day. We thank you for your participation today. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>END </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>16</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication&nbsp;contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995, including
without limitation statements regarding: future expectations, plans and prospects for Solid Biosciences Inc. (the &#147;Company&#148;), AavantiBio and the combined company following the anticipated consummation of the proposed merger; the
anticipated benefits of the merger; the anticipated timing of the merger and private placement; the anticipated milestones, business focus and pipeline of the combined company; the expected cash and cash investments of the combined company at
closing of the transactions and the cash runway of the combined company; the excepted management team and board of directors of the combined company; the <FONT STYLE="white-space:nowrap">Company&#146;s&nbsp;SGT-003&nbsp;program,</FONT> including
expectations for filing an investigational new drug application (&#147;IND&#148;) and initiating dosing; <FONT STYLE="white-space:nowrap">AavantiBio&#146;s&nbsp;AVB-202&nbsp;program</FONT>
<FONT STYLE="white-space:nowrap">and&nbsp;AVB-401&nbsp;program,</FONT> including expectations for filing an IND <FONT STYLE="white-space:nowrap">for&nbsp;AVB-202,&nbsp;and</FONT> other statements containing the words &#147;anticipate,&#148;
&#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148;
&#147;target,&#148; &#147;would,&#148; &#147;working&#148; and similar expressions. Any forward-looking statements are based on management&#146;s current expectations of future events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with: completion of
the proposed merger and private placement in a timely manner or on the anticipated terms or at all; the satisfaction (or waiver) of closing conditions to the consummation of the merger and the private placement, including with respect to the
approval of the Company&#146;s stockholders; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement or the private placement; the effect of the announcement or pendency
of the merger on the Company&#146;s or AavantiBio&#146;s business relationships, operating results and business generally; the ability to recognize the anticipated benefits of the merger; the outcome of any legal proceedings that may be instituted
against the Company or AavantiBio following any announcement of the merger and related transactions; the ability to obtain or maintain the listing of the common stock of the combined company on the Nasdaq Stock Market following the merger; risks
related to the Company&#146;s and AavantiBio&#146;s ability to estimate their respective operating expenses and expenses associated with the transaction, as well as uncertainties regarding the impact any delay in the closing would have on the
anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company&#146;s cash resources; costs related to the merger, including unexpected costs, charges or
expenses resulting from the merger; changes in applicable laws or regulation; the possibility that the Company or AavantiBio may be adversely affected by other economic, business and/or competitive factors; competitive responses to the merger and
private placement; risks related to the Company&#146;s continued listing on the Nasdaq Global Select Market, including the Company&#146;s ability to regain compliance with Nasdaq&#146;s minimum bid price requirement; the Company&#146;s ability to
advance <FONT STYLE="white-space:nowrap">its&nbsp;SGT-003&nbsp;program</FONT> on the timelines expected or at all, obtain and maintain necessary approvals from the U.S. Food and Drug Administration (&#147;FDA&#148;) and other regulatory authorities;
following the merger, the Company&#146;s ability to advance the programs acquired from AavantiBio, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;AVB-202&nbsp;and&nbsp;AVB-401&nbsp;programs,</FONT></FONT> on the
timelines expected or at all, obtain and maintain necessary approvals from the FDA and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data
safety monitoring board; replicating in clinical trials positive results found in preclinical studies and early-stage clinical trials of product candidates; whether the methodologies, assumptions and applications utilized to assess particular safety
or efficacy parameters will yield meaningful statistical results; advancing the development of product candidates under the timelines it anticipates in current and future clinical trials; successfully transitioning, optimizing and scaling the
Company&#146;s manufacturing process; obtaining, maintaining or protecting intellectual property rights related to the Company&#146;s and AavantiBio&#146;s product candidates; competing successfully with other companies that are seeking to develop
Duchenne treatments, Friedreich&#146;s ataxia, BAG3 and other gene therapies; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;SGT-003,&nbsp;AVB-202,&nbsp;AVB-401&nbsp;and</FONT></FONT></FONT> other product candidates; achieving the Company&#146;s other business objectives and continuing as a going concern.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company&#146;s actual results to differ from those contained in the forward-looking statements, see the &#147;Risk Factors&#148; section, as
well as discussions of potential risks, uncertainties and other important factors, in the Company&#146;s most recent filings with the SEC. In addition, the forward-looking statements included in this communication&nbsp;represent the Company&#146;s
views as of the date hereof and should not be relied upon as representing the Company&#146;s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company&#146;s views to
change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>17</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication&nbsp;is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the
proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information Will Be
Filed with the SEC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the merger and the private placement, the Company intends to file with the SEC preliminary and definitive proxy
statements relating to the merger and the private placement and other relevant documents. The definitive proxy statement will be mailed to the Company&#146;s stockholders as of a record date to be established for voting on the shares to be issued in
the merger and the private placement and any other matters to be voted on at the special meeting. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS, ANY AMENDMENTS OR
SUPPLEMENTS THERETO AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE MERGER OR THE PRIVATE PLACEMENT OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE COMPANY, AAVANTIBIO, THE MERGER AND THE PRIVATE PLACEMENT. Investors and security holders may obtain free copies of these documents (when they become available) on the SEC&#146;s website at www.sec.gov, on the Company&#146;s
website at<U>&nbsp;www.solidbio.com</U>&nbsp;or by contacting the Company&#146;s Investor Relations via email at clowie@solidbio.com or by telephone
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at&nbsp;607-423-3219.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, AavantiBio and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders
of the Company in connection with the issuance of the shares in the merger and the private placement and any other matters to be voted on at the special meeting. Information about the Company&#146;s directors and executive officers is included in
the Company&#146;s most recent definitive proxy statement filed with the SEC on April&nbsp;28, 2022. Additional information regarding the names, affiliations and interests of the Company&#146;s and AavantiBio&#146;s directors and executive officers
will be included in the preliminary and definitive proxy statements (when filed with the SEC). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These documents (when filed with the SEC) will be
available free of charge as described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">InComm Conferencing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>18</B> of <B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>www.incommconferencing.com</U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>On September&nbsp;30, 2022, Solid Biosciences Inc. published the following post on LinkedIn: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Today, Solid announced it has entered into a definitive merger agreement to acquire AavantiBio, Inc. and a securities purchase agreement for a concurrent
$75&nbsp;million private placement. See our press release for more info [Link to Press Release on Solid&#146;s Website] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g391920g0930212923287.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>On September&nbsp;30, 2022, Solid Biosciences Inc. published the following post on Twitter: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g391920g0930212923522.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication&nbsp;contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995, including
without limitation statements regarding: future expectations, plans and prospects for Solid Biosciences Inc. (the &#147;Company&#148;), AavantiBio and the combined company following the anticipated consummation of the proposed merger; the
anticipated benefits of the merger; the anticipated timing of the merger and private placement; the anticipated milestones, business focus and pipeline of the combined company; the expected cash and cash investments of the combined company at
closing of the transactions and the cash runway of the combined company; the excepted management team and board of directors of the combined company; the <FONT STYLE="white-space:nowrap">Company&#146;s&nbsp;SGT-003&nbsp;program,</FONT> including
expectations for filing an investigational new drug application (&#147;IND&#148;) and initiating dosing; <FONT STYLE="white-space:nowrap">AavantiBio&#146;s&nbsp;AVB-202&nbsp;program</FONT>
<FONT STYLE="white-space:nowrap">and&nbsp;AVB-401&nbsp;program,</FONT> including expectations for filing an </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
IND <FONT STYLE="white-space:nowrap">for&nbsp;AVB-202,&nbsp;and</FONT> other statements containing the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;would,&#148; &#147;working&#148; and
similar expressions. Any forward-looking statements are based on management&#146;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from
those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with: completion of the proposed merger and private placement in a timely manner or
on the anticipated terms or at all; the satisfaction (or waiver) of closing conditions to the consummation of the merger and the private placement, including with respect to the approval of the Company&#146;s stockholders; the occurrence of any
event, change or other circumstance or condition that could give rise to the termination of the merger agreement or the private placement; the effect of the announcement or pendency of the merger on the Company&#146;s or AavantiBio&#146;s business
relationships, operating results and business generally; the ability to recognize the anticipated benefits of the merger; the outcome of any legal proceedings that may be instituted against the Company or AavantiBio following any announcement of the
merger and related transactions; the ability to obtain or maintain the listing of the common stock of the combined company on the Nasdaq Stock Market following the merger; risks related to the Company&#146;s and AavantiBio&#146;s ability to estimate
their respective operating expenses and expenses associated with the transaction, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company upon closing and other
events and unanticipated spending and costs that could reduce the combined company&#146;s cash resources; costs related to the merger, including unexpected costs, charges or expenses resulting from the merger; changes in applicable laws or
regulation; the possibility that the Company or AavantiBio may be adversely affected by other economic, business and/or competitive factors; competitive responses to the merger and private placement; risks related to the Company&#146;s continued
listing on the Nasdaq Global Select Market, including the Company&#146;s ability to regain compliance with Nasdaq&#146;s minimum bid price requirement; the Company&#146;s ability to advance
<FONT STYLE="white-space:nowrap">its&nbsp;SGT-003&nbsp;program</FONT> on the timelines expected or at all, obtain and maintain necessary approvals from the U.S. Food and Drug Administration (&#147;FDA&#148;) and other regulatory authorities;
following the merger, the Company&#146;s ability to advance the programs acquired from AavantiBio, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;AVB-202&nbsp;and&nbsp;AVB-401&nbsp;programs,</FONT></FONT> on the
timelines expected or at all, obtain and maintain necessary approvals from the FDA and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data
safety monitoring board; replicating in clinical trials positive results found in preclinical studies and early-stage clinical trials of product candidates; whether the methodologies, assumptions and applications utilized to assess particular safety
or efficacy parameters will yield meaningful statistical results; advancing the development of product candidates under the timelines it anticipates in current and future clinical trials; successfully transitioning, optimizing and scaling the
Company&#146;s manufacturing process; obtaining, maintaining or protecting intellectual property rights related to the Company&#146;s and AavantiBio&#146;s product candidates; competing successfully with other companies that are seeking to develop
Duchenne treatments, Friedreich&#146;s ataxia, BAG3 and other gene therapies; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;SGT-003,&nbsp;AVB-202,&nbsp;AVB-401&nbsp;and</FONT></FONT></FONT> other product candidates; achieving the Company&#146;s other business objectives and continuing as a going concern.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company&#146;s actual results to differ from those contained in the forward-looking statements, see the &#147;Risk Factors&#148; section, as
well as discussions of potential risks, uncertainties and other important factors, in the Company&#146;s most recent filings with the SEC. In addition, the forward-looking statements included in this communication&nbsp;represent the Company&#146;s
views as of the date hereof and should not be relied upon as representing the Company&#146;s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company&#146;s views to
change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication&nbsp;is not
a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities
nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information Will Be Filed with the SEC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the merger and the private placement, the Company intends to file with the SEC preliminary and definitive proxy statements relating to the
merger and the private placement and other relevant documents. The definitive proxy statement will be mailed to the Company&#146;s stockholders as of a record date to be established for voting on the shares to be issued in the merger and the private
placement and any other matters to be voted on at the special meeting. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS, ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY
OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE MERGER OR THE PRIVATE PLACEMENT OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY,
AAVANTIBIO, THE MERGER AND THE PRIVATE PLACEMENT. Investors and security holders may obtain free copies of these documents (when they become available) on the SEC&#146;s website at www.sec.gov, on the Company&#146;s website
at<U>&nbsp;www.solidbio.com</U>&nbsp;or by contacting the Company&#146;s Investor Relations via email at clowie@solidbio.com or by telephone <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at&nbsp;607-423-3219.</FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, AavantiBio
and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of the Company in connection with the issuance of the shares in the merger and the private placement and any other
matters to be voted on at the special meeting. Information about the Company&#146;s directors and executive officers is included in the Company&#146;s most recent definitive proxy statement filed with the SEC on April&nbsp;28, 2022. Additional
information regarding the names, affiliations and interests of the Company&#146;s and AavantiBio&#146;s directors and executive officers will be included in the preliminary and definitive proxy statements (when filed with the SEC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These documents (when filed with the SEC) will be available free of charge as described above. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g391920g0930212923287.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g391920g0930212923287.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? FX# 2(  A$! Q$!_\0
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M0 4444Q!1110 444E !2TE% "T444 %%%% "4444 %%%% "T444"%%.I*6@
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M1:LS6VECQ+'H::<%6.Z6%[DS.9)!G#9&<#/L.*P;N[GOKEKFX??*P + 8Z#
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M<$@P;C@$<[64'TQ4<MCID]SJFFP61@EL8V=+GS69G*==X/'/MBLJ[UV^O(#
MQ@AB9@SK;P+%O(Z$[1S2W&OZC=6K022QX< 2.D2J\@'0,P&319@YQ9OZM;+<
M#4F+NK"*U48<A>0!R.A_&GVJ:?9:GJNG6]CLD@LY%^T>:Q9SMY)'3'TKEYM7
MOITF62;*S*BR?*!D+]W\JLMXEU1H6C,T67C\IY!"F]UQC#-C)HY6/VD;W#1-
M-CU6VO(%0F\55>$@]L_,,=^*V;[0=+A6>^MU=K&&W*G+GF<';U^O.*YG3]0N
MM+NA<V<OE3!2H; /!&#UIPU.\&FOI_GG[*\OFLF!RWKGK3:=R8RBE9HZJ[CL
M[*UUL262W31QP8>:9RW('&<T3#3KJ]T:PN+#S6GM%4S><RE.N-H'''OFN=77
MM06:>5I(Y#<((Y5DB5E8 8'!&,CUJ'^U;W[5;W/FCSK=0L3;1\H'3BIY67[1
M%O0["UN=?-K=JTD""0L%;:3M!QS5_P#XD_\ 8]OJ)T9-[W)MS%]HDV8_O=<[
MOQQ6!;WUQ:W9NH9-LS;@6P#UZT?;;C[&EIO_ '*2>:JX'#>N:IID*22.BNO#
MMM-<75G8(XN+>[5&RQ.8FZ'\.>:H16^F2^*_LBH18M(85^<YSC ;/UJ:PUS[
M*U]JDMX[ZE<Q-"(EBP.>-Q/3IV%8".R2*ZL0ZG<#[TDF.3CHT=?'X5MGMK6W
M(<:@DJO=#=TA8GMVP!^M3:2EG!J.C30PL\4EQ.L:/,VU ,X(&>M<W_PD.J_;
M[B^^UG[1<1F*5]H^9>F,5##JM[;BU$4VW[*S-#\H.TMU^M'*Q\\$]$=';Z?I
M4MG_ &G=I8Q_:+IXQ'<W<B*BJ>=I&26[\US&I16L&I7$5E.)[97(BD!^\M3V
M>M7MC')%&8I(I&WF*>%9%W>H##@TV?4WGTTVAB0%IS/)(J@;B1@  #@"FDTR
M92BT=!X3B^P6,NI/-:Q&XD%N!<RA T7_ "TQGKV%0'1['3%UQ[RV^U&SDC%N
M!(55@Y."2.HQBN>GNYKB"""5\Q0*5C4*!@$Y-6)=8OIK1K:28-$R(C#8,D)G
M;SUXS2Y7<?/&UK;&^NEZ25:_>R80MI@NUMEF;"OOVXW=<46-C97,^EWD$#V?
MVF*X$D<,S8#(IP02<C/<9KG_ .U[[R!!YP\L6_V;&T?ZO.<?GWH@U>^MDMTA
MF"K;AQ&-H.W?][\Z.5ASQOL=':Z-HD%AI_\ :,]DGVN#SI9IKEUECSG&Q0-I
M QWZ\UR#8#L P8 X!]:T+?7;ZVLUM08)8DSY8G@20QYZ[2PXJ&^OS>0V<0B6
M-+:$1 #^(Y)+'ZDTTFB9.+6AT&CZ):SQ16M_;6L4T]M)-&QN7^T$!2RL$'R@
M<=#U%-M;/28AX?@FT[SY-21?.D:=EV;I"@*@<9XSSFLR+Q+JD,,<<<T8,<?E
M+*85,FS&-N[&<8-5/[2NP]B_F_-8@"W.T?( Q8?7D]Z5F5SQ2T1M2V>G:+;6
M;3V?VV6YNI4WM*R>6D<FP;<?Q'KSFH/$%O\ :O'=];;]GG7WE[CVRP&:J0>(
M-1@21%DB</*9AYL*OY;GJR9'RGZ51NKN>]O);NXD+SROO=^F6]>*:3N*4HVL
MCH+BSTNY;6[*VL3;2:;$\D5QYK,TFQ@I#@\<Y[8P:<VC6/\ PEEY8"-OL\5D
M\RKO.0PAW@Y^M95WK^HWMM);S2Q[9<><Z1*KS8Z;V RWXU*/$VJB+8)H@QB\
MAI?)7S'CQMVLV,D8I68^:!)J46G6.CZ:L=D7N[RT6:2=Y6PAW$?*HXYQSFBT
MAL;+P\NJ75DM[)-=-;I&\K(J!5#$G;@DG/'/:LJ>[GNDMTF?<MO$(HA@#:H)
M./U-6;#5[S3HI(83$\,C!FBFB61-PZ-AAP?>G9V)YE<U%BTRQLM-EN-.%TVH
M%W;]\R^4@?:%3'4]\G/:H-0T4:;>WG^D6LT-K<&/RGF"RN ?[HYJ"TU_4+./
MRXGA*AS(GF0(_E,>I3(^7\*SW=I9&DD8O(Y+,S'))/4T),'*-CMM;2QN-7U2
M\GLE9+"VB80B9P)2P11GG@#/;%48=)T^\B@O4MS#'/9W,A@$A(22,<$$\XZ<
M&L9-;U!;^2]\Y6FD01R;D!5UP!@KC!& *<=>U'[?%>"95DB4I&JQJ(U4]5"8
MQ@Y.1WI*+L4YQ;NT:.C:397EMH[SQLQN;\P2D,1E H.!Z4"RT[4[&[:VL_L;
MVUS'&KB5G+JS;?FSQGOQBJ+^(=2>2W<211BVD\V%(X554;U  JDE]<QV]Q D
MF([AE:08')!R.>W-.S%S1V.IB%A!+X@T^UL?):WM9(Q/YK,SX(!+ \<^V*;?
MZ-HEC#-:S7%E'-';!UE^TN9VD*@@%,;<'./ZUBS>)-3G@EB>6+$R>7,ZPH'E
M7_:;&34,NOWKV7V>=H'4)Y8DD@0R!?0.1FERLKGCV-2YAT.RFTVWN+1PD\,<
MMQ<&5B4SU"@<8]>OM5#7[>*U6&:&TM8K60L(Y[6=I4E_[Z.01Z<5ERZY=/<P
M3[D>2! B%XU(VCH"",'\:AU'5[O4Q&DYB6./)2*&)8T!/4X'?WIV8FTTRO)<
MLW"<#U[U7I:2F0)1110 4444 )1110 4444 %%%% "T444 %%%% !1110!UW
MPSTS^TO'%F67,=L&G;\.!^IKZ+KR?X+:7MM=1U5UYD<0H?8<G]3^E>L5RU7>
M1ZF%C:G?N%%%%9G0%%%% !1110!\M444M=QX(E7+32]0OEW6EE<3J21NCC)&
M1VS^-5*V9+Q1X/MK1+C$@OGD>)6YQL !(_.DRHI=3/@TV^N;I[6"SGDN(\[X
MU0[EQUR.U.BTR_GNY+6*RN'N(_OQ",[E^H[5V#ZE875SK-NILKB:Y-NZ&YG:
M..4*F&&]2.<\X)YQ521K?4KF]FN_[--]%'%%% +UE@9 .27SER..,U/,S3V:
M[G-+IE^]Q);)97#3QD*\8C.Y2>F15FYT2>#3(+G9*9F>59HMG^J"8R3^=;^J
M:K;?\3DVM["#-96\2&%SAB"-RJ3R<52L=4AL[#11YBOMGF2XB!R?+? .1[C-
M%V'+%.U_ZN<X891 LYC<1,VT/C@GTSZU>O-"U*QMK:XGM)%CN%!C(4]SP/J?
M2KGB@1V5S!HUO('AL%(+#^)V.2?RP/PK3M;VTAN?#NHRW$+V]M%Y,R&3YT?+
M<E>N.0<T[NUQ*"NTSFI])U&UEBBGL+B.27B-6C(+_2FW6EZA90I-=65Q#$YP
MKR1D FNNCOQ9WVGQ2#28+7[<LYDMKMI3D9^8[F.T?E6(MZDFDZ\LUR&DFF1X
MPSY+G?R1^%";!PBC%,$JPI,T3B-R0CD<,1U -68=(U*XEDBAT^YDDC +JL9)
M7/3-;7A@VUY;3V5ZV(K9A>H2/[OWA^(JY8ZM%J6F2AHK"2]-ZUPR7EPT((/0
MJ0P!QZ&AMA&"?4Y>UTO4+UY$M;*XF:,X<)&3M^M)!IE_<NR065Q*RL58)&3M
M(['TKIXVL[R>?4)VTYKXW8,R/=LD4:#'S( <O^9J'6]3A>PUB.VO$(N+]7"Q
MO_K$V]?<4<S#DBE>Y@-I.HI:&[>QN%MAUE,9VC\:CM+&[OY3%9VTL[@9*QKD
M@5T%SY-YHIFU.6S$\< 6WFMKG,DF.B/'_7BJ6AVUE-9W;RM;M=J5\N&YN##&
M5[DD$9(],T[Z"Y%=(SX]+U":ZDM8[*=KB/[\80[E^H[4XZ/J:W:VAT^Y%RPW
M"+RSN(]<>E=C,]I?W&J!I[8V#P0KYBW'E(9%_A$C9_(@U2N'E>;4;:XDM;::
M]MXQ:RK< QNB]O,]_4U/,RW32.4N;2XLYS!<P20S#JCK@U<O=!U/3UMVN+.4
M"X4&/"DY)Z#Z^U6-=EC%EIME]HCN+FVB999(WWJ,G(4-WQ6NEY;)J&E:@UW!
MY(M/LY/F9:*3:1DKU 'K3NR5%7:.8O--OM/*B]M)K<N,KYB$9J[;Z#<WNC17
MMG%/<2O.T;11IG:  <U9NPNG^');&XO+>YN)KD2QK#,)0B@<L2.F?2GVB"^\
M)16,.H6T%PMVTC133B/*X&#D^E%V"BKV,:'3;ZXF:&"RN))$;:R+&25/H?2I
M'TNX"P+'#</<2!MT7DGC:<'!_B_I70ZGJUN]IK:VUXI>4P1[E;!FV@[B/44:
M5J5M;V^DDW<<<D-G<JQ+X*L<[1]31=AR1O:_]7.:N=,O[-XDN;*>%I?]6'C(
MW_3UI]SH^IV4/G75A<0Q9QO="!GZUNZ!=$V&GQ)*KW2:D9-C')5-HW-CTZ\T
MS7H-FEO'8_9Y+".Y,DDD=X)W#MTS@#:.*?,[V#D7+<P[72M1ODWVEC<3KS\T
M<9(XHETK4;>U%U-8W$=N3CS'C(7-:27L:^'M*MUN0&COFDD0-@J,C!-7KK4H
M)=0\4.]VLB3H!#E\B3$@.%]>*+L7+&QSSZ9?QV2WKV4ZVK=)C&=I_&A]*U".
MR%Z]C<+:D ^<8SMP>AS77:KJD4D=Y>V,6E&"YMQ$TC7+^=MP/E\HMC(QZ8XI
MC?V786.J);S61AFL#'!,;IGFF;Y3@IG"]^,4N9E>S5]SE_[&U3[,UQ_9UUY"
M+N:3RC@#U^E(VG2L+9;:.>>2:'S2@A((Y/3^\/>ND74[<^,=/E:]3[+'9+$S
M%_D7]R05_P"^OUI+/4K:&2R=;N-&CT6:+(?!60[L+]:.9BY(]SFY]*U&UGB@
MGL;B.6;_ %2-&<O]/6K=OX9U>:^MK:2PN(?M$@C5WC.!D\G\*V?#5T#9Z7$)
MD,L5].\H=N8X3$ S'^Z.O/K3L"SNM$:)[8:3:WX+3QW@G*LQ!.\@# P.F.QH
MYF-0C:Y@:SI?]FW4D<4-Z(8F\MWN8@GS<D8QV(Y%);Z2[V.ISS^9#)9PQRK&
MR_?#N%'X8.:TQY>IZ-J=C%>6R3G4OM*B>8('CVL,@G@]1Q5O5+VR8:XD5Y#*
M'TZSBC96XD92FX#Z8-%WL+E6_P#74Y^PT34=3M+FZL[62:.WV[]JDDDG&!ZG
MO]*A.FWXM&NS9SBW4!FE*$* >G/O6EHA2;1M9L!<10SSI$T0FD"!MKY89/&<
M58OM3@%[X;9Y?/M;.T@\V-#D*0Q+#'KTIW=Q<L;)F-<Z9?V4,<UU97$$<GW'
MDC(#5))HVJ0+"TNGW*"9@L9:,C<3T ]ZZ?5;N!Q=H?[*33]0ND:6XM[IY)F7
M?G?L9CM(!.>!CI3=0DL;/0]5MHGLD,EQ"\ ANFFDE17/S,2< X^AZTN9C=-:
MZF#=^'=6LK]K*2QF:91G$:$AAQR/49.*3^P-8WR)_9=WNC7<X\H\#UKH;ZZB
MAU;Q!=QW\!COK-C;M',"6R5^7'4'KQ]:K6^I1"3PFK7@"6KDS#S.(OWN>?3C
M]*.9V!PC?^NY@VFFWU\CO:6<\ZQ_?,:$A:=:Z5J%\NZTL;B9<D9CC)&1U%=3
M:WUK-81Q6T6G2W%M>S2D7=RT/5LJZD, W3ZUE:OK"S:*JM<1+.^I2S20P/P,
M@8(]LYP:?,Q.$4KW*-MH.IW=K=3PV<K+;,%D&PY!],>W>LQF"#YCBNKU"_@U
M(Z_;VM];B686\D;/,%63:!OP3QFN%))/)R::=Q2BEL3R7/9!^)JLS,QRQR:6
MFT$A3:=24#$I*6DH 2BBB@ HHHZG &<T )16WIGA?4=28$(((S_')_A77V/@
M'3H%#732W+]\G:OY"N6KC:-/K?T-84)SV1YJ.3@<GT%78-(U*Z&8-/NI!ZK$
M<5[!::;9V)5+:S@B7U5!G\ZV.?+Z\5YDLZO*T(?>SIC@K[L\1'A?7#_S#)A]
M<#^M!\+ZV.NG2?\ ?2_XUZY,1N-53UK99C4?1'0LOIM;L\I?P]K$8RVG7&/9
M<_RJC+;SP'$T,D9_VT(KV3<:9(!(,, P]",UI''RZQ$\NCTD>-45ZE=>'M+O
M,^;9QJQ_BC^4_I6#?>!/E+V%U_VSF']171#&TY:/0YYX"K';4XN@]*MWVF7N
MG/MNK=D]&ZJ?QJYX6TLZSXGT^Q"Y628%_P#=')_E74I)JZ.3DDI<K6I] >!M
M*_L?P?I]J1B0Q^9)_O-R?YUT5(JA5"CH!@4M<;=W<]F*Y4D%%%%(84444 %%
M%% 'RU2T45W'@A116O;:;8II,>HZE/<I'/,T4*6Z*Q.T#<QW'H,CBAL:39D4
M8KHI/#MK8Q:A-?WDOEVLL2(((P3,LBEE(R>.!5BWT+2HC>O<37,UL=/^UVSH
M@# $X.1G[P/'I2YD5[.1RU6+&]ET^Y%Q"D+2 ?*98PX4^H![UMIHR7EOIQ:X
M\NU^SSW#N(1O6-&YZ?>)]Z;:>'[34IK%[*[G6UN+@V\AFC7?&V,@\'!!%+F0
MU"5]# EEDGF>65R\CL69B>23U-,K<.CZ?<6;7%E>SA8;A()FN8PJX8D!Q@].
M.AJ/7=*@TF588UOM^XX>>-1'(O\ >0J3D4[H3@[7,:BN@_LS3I/#EA+']I_M
M"YN&B!P-A(QP>>G/UI+C0['-];6=W<27EBI:421A8WV_>VD'/'OUHYD'(S+3
M4KF+3I+&+RTBE/[QEC =QZ%NN/:J=:NE:;:WEI?75W<2Q16B*Y$2!F?)Q@9-
M6'T2V-Q9/;->W-G=QLZ"*$&92O!!&<?C1=!RR:,*BNOA\-:?;:B$O3>>3)9/
M<)&Z*)$(_O8./IBJ=OHIU.UTJ&TE)CNKB14WPJ'4 #))'7Z4<R'[.1S=+763
M>#0LMIA[RWCFN/L["[B57_WE /(JJFBZ7*))+>[NY$M;A(KC?$HW MC*<_SH
MYD'LY+<RK/5+BQADA18)89"&:*>(2+D=\'H:CO;ZXU"82W# E5VJJJ%55] !
MP!702Z#IESK]]:6<EV$M@2(%5/,D/HF3S^/-<_>0Q0WKPPK<!5.-LZ!9 ?0@
M4)IA)22LRM171S^&D72S>(-0AV2(C"[A5 X;NN#GCWHNM T^.;4+2VOKF2[L
MXS(2\2B-P.H&#G/-',@]G(YRBNPT?2M/T_7+6WGN)WOS 963RE,0RA(7.<YQ
MWQ6;X4CM9/$D?VH.0H=D"H&&0"><^E','LW=+N8-%=/9:6GB34))';593++Y
M:SK FU?0N<X_ 57BT.PALXY[^\N5:2Z>U5+>-3RIQNR3TYHYD+V;W1C6EW/8
MW27-N^R5,X.,C!Z@@]15BZUBZN[;[,5MX8"VYH[>%8PS>IQUK3O= L8%U&&W
MO;B6ZL &D+Q!8W&<?+SG/UJ[<VOD0:]$QC=E6UPRQ!,9/H*+H:A):'(45U\G
MA:2[U#4II!<SQV\XA"V4"!F.,YVY  %1'PE'!<7T<\MU<-;,H$-G&IEVD9W%
M2>@Z$#/-'.@]E(Y6C%:&FV$.HZPMB)9(TD++&S*-V0"5!'N1BM.+PK)-8:?,
M)SY]U.L<D6W_ %2,3M;\<-^5-R2)4)/8YREKK+BST@:-I45S<W(4SS11M!$I
M9AOP&;)_052GT*TTR.>75;J?RDNFMHQ:Q@LY7JQW' '(XI<R&Z;1CV5[/I]Q
MY]NP#[2A#*&5E/4$'@@U->:M<WMNMNZP0VZMO$5O"L:[NF2!U/UHU;3CI>HO
M:^:)4 5XY ,;D8 @X[<&MC18!<:!'&-JN^M6Z!R@;&5/8]1[4-K<$I7Y3F>*
M*[)]&-YX?WR,(K:TU*Z:ZN5C^X@V 84=R>@Z?A5/2O"PU&PCO2E^\$\S11?9
MHE8HH.-[Y(]>@]#1S(?LI7LCF:6M)=%G?Q)_8@DC,WV@P>8/N\'[WTQS5EM)
MT^ZM;B;3+NY?[+*BS+<1JNY&;:'7!]>Q]:=T3R,Q**UIM(ABU#7;7[2Q_LN*
M20':,R;6"X/IUJQ<Z+IL.LVND?VE,MS,(W>5XU$<:N@;;DGEN0!T'(HYD/V<
MC"R ,G J-KE%X'S&IM;LH["\6!8M0BD"Y=+Z-58>F-IP1[U;\.*K1:WN4-C2
MYB,C.#\M%]+B4-;,R&G=^^!Z"F5TFK:)_H\TZ7 DN+:VM9&B6$(#&ZCGCJ02
M 3WSFK,'@SS)KL;KNX6S2(31VL2M)YKC)49.,*.I-+F17LY7LCDJ2M37M(;1
M-4-H79U,:R*77:P##HP[$=#6757N0TT[,*;3J;2 *2EI*!B4E+24 )12@$D
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M *C8C/6M5&Q+EV#;D5&\((J0R*O4U7DOH(_O-6BE'9DVET*\MN <U6DA./\
MZU6WOX".&7TY.*CFG3;RX!/85+A%[#4VMS"O8\!L_C7(ZI$[.%49P<BNNNF+
M[PO/K6!?6S$XSS4Q5I#D[Q9?\,"2.SDA?)"MN7C& >U:[GYL5F:$K^8BK"P,
MB[3CG)%:L\+1O\XQ3JQ?-<X5V'1\T\G%$(&VE(YK(H;WJ1*92C-#T NV%V;&
M_AN!T4X;W!ZUZ&K!E# Y!&0:\PY/6N[\/77VK2(LG+1_NV_#I^E=.&GJXF-6
M.ES5HHHKL,#YU(IA%1[F_O&FDMZG\ZZ.8\1(D*U&P'K3"#6M&EII_A^WOGL8
M+R:YN'C/GEML:J!P ".3GK[52J%J%S(++W8?G3?-3^\*Z>]TS3])M=6N5L$N
M&@GMQ$L[,1$)$+$-@C..GY4?V9IRFYOCIRLATI;U+4LVV-]X'KG;WQZ&M8U$
M*5%G+^<GJ?RI//7T-=+:Z9I^HIIU^UFD"R1SM+;1,0DIB&1MR21GH>>U-TVT
MT_68K&[>PAM_].2WDC@+!)48$]R<$8_6M5-6.=T7?<YEKCT3]:B-RW90*ZK3
M[RR#:YY6CV2QV]I($#;V+ ,!\QW=?IBLZ2QM'_X1UUMU4WK-YRJ3AOWF !^'
M%5S^1*I=4_ZO8Q/M$GJ/RJ11</"\P60Q(0&<#A2>F3717L6FZ39O,NEV]Q*=
M2E@'G%BJQKT& 1S[U/+IUE8S:@8[<-'%=V_EQN[%0&P2IYYZUDZAUQHG,P+<
MMOE@$V8AN9TS\@]21TIA)9BS$LQ.22<DUU>I+;W>H^)2+6&%K:/Y#"6&3N49
M(SS_ "J:_P!/T"PC>SGGLT<6RNC!93<&0KD'.-N/:HYS;V1Q^*7%=#>0V5SH
M[2Z3;V3QQ1J9B=PN8CW)R<$9[BDLYX8?!EX6LK:5OM*+OD#9Y!]#VHYQ>SU.
M>Q4L4%Q=Y6)7E\I"Q .=JCJ?I73BRT]=6M=$-A$ZS0*S76YO-W%<[@<XP/3%
M4O"VR/4[\/'YZ):393.-X ]J?/I<ET];'-FI46YDMY!'YS01_/(%)*K[D=*Z
M?3;+3M7&EW<EA% LETT$L4)8)(H7.1DD@U3B%G>VFL/'8Q6RVT:B,1,W/SXR
MV3R<5?.9>S9SX%/"UU\]GICZQ>Z1%ID$:1VQD6<,QD#A0<YSC'MBDC@TFTL(
M)9[:P:WDL]X>9V\]I?9<CC/MBI=0I4GW.2VT;*V=#MK>9KVYN(5F%K 95A)(
M#G..<<X%:UCI]AJ2V-XUG'")EG5X8R0A**2&&3D?G2<[%*FV<?LI"E=-I.FV
MESI]G++"&:345A9LGE,#(K/UI[8WLL%K916T4+LBE22S8/5B3R::EK8'"RN8
MY2DVE2&4D$<@@X(KMVL=-&L6FDC2XMES;*[3[F\P,4SN7G&!Z8JHEK86/]DV
MSZ?#>&^YEE<MN&6VX3!P,?C1SH'29R#H6)8Y)/4FHBE=U?P6UMH4.GK;6S;M
M1D@%PP.\#Y1NSG&?TIFLV&@6J7MF);)+B A;=8EF\YF! (D+#:<CTIJ2)E2:
MZG"%*=%;37$RPP1/)*WW41<D_05V]W9:4^KZII,6E011P6SR1SJS^:'4 ]<X
MP>>,5*5M+S6/#ED^GVT:262NS1%E?[C'&=W3-+F%[/7<\]*D'FK,>EWTRQ-'
M:R,LR.\9 ^\J?>(^E=;H&C6LCV5KJ5OIP%]N:/>9#<.G."NWY5Y'&:GTN/;;
M:,HSQ9WX_P#0JF3ML.-.^YY_4\<%S>"5HTDE$$6]SG.Q!QGZ<BNHM='T^>"T
MUIK8?V=%9NUW$"<&=/E"Y[;BR'\353PDR)_;DDMN)T739&,1) ;#+UQSBDV'
M)KJ<W17;:7H^F:W'INHRVL%FK+=>=#&7$4ODJ&#8Y8#YL'']TXJO(?"BW-A-
M--92-F5;A+*.80#Y?W3,K8;&[[P!Y I<P>S=KW.1I\<;S2I%$C/(Y"JJC)8G
MH!7<6,:65QJ4\FF:1)!+H\LT$EMO:&4!@"1ELCN".#Q6#I&GV]UJ.G7+7=F%
MGO(U:RC=A(JE\8'H,>^<4<PG#8Q'1HW:-U*NI*LI&"".H-%=5=+IVEZ0MV=*
MM[NXDU.YA)N&<J(T(P, CGGK537-$M;75M42WO;6VBMWS%;S2-O8%0V%XYZX
MYIJ0G!HPE4NRJHRQ. /6I9[>:TN9;>XC:.:)BCH>JD=170:N++2M2AT>WTVV
MW*L#&\<L979@K%ASC'.,8K3O[.-/$FL7M[#IOV674G@1[WS&+,#DA%3V(Y-'
M,/V9Q(I:[$V.C6FKZGID45D;Y+O9;IJ)?RVCQ]U64C#9/5JAL[2SFM7L(+&P
M.M))*L]K=EPY(/ B8'''/!Y/O1S![-]SE**.G!HJC,=%-- ^^&:2)\8W1N5/
MYBF.S2.7=F9B<EF.2:*2D @4LP4=SBO4;1OLUC! O 1 *\WT^/S=1MT]7%>@
M_.3\M>+FTFW&"*4K%D$R/\U6ERG%9K,\+!FZ>U3&]RG %>?"-EJ4I+J%U. 2
M,CZ5F3[9OEVT^2*6YDW!MJ^M7;6V"GYP#Z&L71G)W,.651^1@S69@*RHI!!!
MR*]0L9 ]C$^<Y4&N6N+0S1E8XRQQT5<UTNDJ18P(RD$)@@C!%=<$_A/7RJ'L
MYR70N8!JK<7T5LN6R?I3[V3R(2Q.*\WU+Q7>ZA=36VD1+*4RHXSN(Z\]!5N5
MM.I]'3@Y*_0[&;7HB=J/FI+;4!<2* >M>36VB>)=4U!9=1@GM;3DN690WX#-
M=GX2TF\LI_,N)69 WR@L2<>^:SJ\\=;G134)1;M;U.JU)I(+=I #TKS>_P#%
M$B7I57*NF02!DG\*]4O")+1^.,5PZ^';5KJ28Q(Q<\[C6SI]3*%3HSDAXDU"
MW7[>MBT\98JLTC?+D=L+4D?CG6;F-G?2)@@X(\MAGZ5Z%;::]K'LCM5"]M@&
M*E_LV[N)06BC1 >IX/Z41M:U@DG>_-^1R&C^((+P[FRK9P8W&&!]Q6M=JC .
M!E3TS741:5:6R?-;QNW7<4%9^L1VYC 1,;><]JMQ:1BY)O0Y:UU"6S$UQ&A)
MB4A!ZL>!47A[4-3GU"8:C/E) =J;<!2*G:(-/(44M'\I(7KGI5Y+$1NL\0ZM
MD?7O1*\G8WH1A[.46MS8C.!3LY- &%'TH#"L-F>< J3;Q2+3\<53$1GK72>$
M9\37-OGJ X_D?Z5S39S6IX:D,6MQ#LZLI_+/]*JE*TT3-7BSO****](Y3YNQ
M2&G45M8\4815JSU2^TY'2UG*(YW%2H89'0X(.#[U7Q6G::;8OI#7][=3Q+]H
M\A5AB#\[=V3DBDRXWOH-M->GM-+OHUFD-[<W,<I=U#AP V[=GKR13;'7[BWE
MU.ZGN)6O+FV\J.0 '!W*<$= , C%-O=%FA>,VK?:[>:)IHI47&47[V0>A'<5
M0^QW#11S+"[1ROY:,!G<WH/?FKBT#<D.GU?4)[R*[DNG\Z'B)D 41_0#@47&
MN:E<7$$TETPD@;=%L55"'U  QGWK2M/#%Z]]]FO;>6%FAD>-5*EF95SC S67
M=Z1J%D85N;22-IN(^C;CZ#&>?:NB,HF,HSM<K6VHW=A=-<VTQ25P0YP"&!Z@
M@\$5)#XBU:TA,4%XR)O+KA%RC'J5./E_"GW>AZI:R0QSV,J/,VR,<'<W]WCO
M[&J]]H>J6, GNK&6*+=LW-C@GH",Y'XU;<63&,T^I6GU&[N4\N:=G3S6FP<?
M?/5OJ:E?5;ZX$HENG83,K29Q\Q7[I_"G7'A[6+:VDN)].FCBC&7+ 94>I&<X
M]\4)HFJ?V?\ ;OL,OV7;N\S ^[ZXZX]\8K)M'7!2+$VN:E="03W1;S(_*D.Q
M077KR0.>@YJ4:[J7V(69NBT(78 R*6"^@8C./QJA965S?S>5:0M*X&XA<<#U
M)/ %7'T/58KJ*U>QE$\HW(@()8>O!Z>]9Z&VH^?6]0N;3[++<9AP 56-5+ =
M,D#)_&H[74KNRAFAMYML4PQ(A4,&_ CK[T[^Q=4%Y]D^PS&XV[PBC.5]1C@B
MDN-'U*TFAAFLY5DGXB  ;?\ 3&::L2[CUU[4X[+[(MXXA"[!P-P7T#8R![9J
MG::A=:=.9K.=X92I7<G7!ZBGW^FWVFE!>6SP[_NDX(/XCBIG\/ZD-(@U(0[H
M)F*J PS]?QJU8SES?<1S:_J<]S#</=MYD&?*VJJA,]< #%58;RXB2>..5E6<
M8E _BYS_ #J>30M5BEABDL94DF)$:-@%L=>,\?C3_P"PM4CO$M&L9?M$B[T1
M0&W#U&.#5:&+YK@-2O?M<EW]H?[1(I1WXR5(QC\JZ>/Q)9I%&%GN?LR1>7_9
MQMD*$XQ]\G.,\^M<_+HFI6TD*364BM,<1@8;<?3CO[5I:?X6OY]4M[.Y@>%9
M,DL&4D =>_6IERFL.9,RK6[GL[G[1:R&&09P5]#V]Q5B36-1EO(KMKIQ-#Q&
MR@*$^@ P*N2Z#=S7<R:?871CB;:1(REL^F1@$^PJM!H^H7,;R0V<K(A(9L8"
MD=02:5T5JM GUW4[AHS)=M^[D$B*J*H5AW  QFL^5GF=W=MSN223W-6;6QN+
MVX$%K"\LI_A6K T/4FNGM5M&,R %EW+P#TYSBBZ0M67-2\2W4Y6*RN)([?[.
MD1!10PPN& /4 _6L^UUG4;&W\BVNF2/)(&T$J3UVDC*_A3X]%U*6>:&.RE,D
M)Q*N,;/KZ4TZ-J(OOL1LY?M.W=Y?'W?7/3'O0K;#;DW<@34KR*SFM%F)@E.Y
MT90W/J,\@_2G7&MZE<VGV6:Y+QX ^9%W$#IEL9/YUI3>'6MX]/$Z7*S7"RL\
M:*&(VYQCGD<>M5=)\/7NJ7%L1;3?8Y90C2KCIG!(!ZXJE*.Y#C+8S6U&]-W-
M=&X?SYD*2/QEE(P14D>M:G##;Q1W1"VQ/DG:I9.", XSCD\>]3)H=]=W-PEC
M;23I%(8\@@9([<GD_2A?#^HMI#:F(?W"2%&!(!&!R<>G:M+Q,K3Z$=OX@U>T
MMXX+>]>-(L^60J[E'H&QD#VS55=2OXEB$=RZ^4KI'T^4/]X=.^:LRZ+J,%D+
MR6RE2W(!WD#@'H2.H!]ZJ0P-/<10J0&D<("QP 2<<TGRE)2ZEJ>_M[?PW_9-
ME+/)]HF6>Y:1-B@@8"J,G/J3WXK+LM0O=+F>:QN'@D==C,N.5SG!]N*V]7TO
M3;"2:TAO+N:_AD\MD>V"HQS@X.[/TR.:+K1=(TV4VFJ:G<+>J!YJ6UN'2)O[
MI)89([XK.ZL:<LK^AD7&N:I<7MO>27CB>WX@:,!!'_N@  >_'-/D\1ZK+=17
M+7*>9$&"8@C"\]<J%P<^]:>FZ+H5_I]U/+J=_'):0^=.J6BD8W!?E.[GJ*PW
MM8Y]2%MI[23))*(X6D4*S9.!D<XYJ="6IK6Y8_X2+5O[02^%XPG2,Q+A%"A#
MU7;C;M/IBJ*7<Z7HO$DV7"R>:KJ ,-G.0.G6MR[\.6NR\BTR^DN[NPD6.X1X
M=BMN;9NC.3D!B!SCKFDO_#UI!%J,=GJ$EQ>:7@W:-#M0C<%8QG.2%8@<@9ZT
M71+C/J8\U_=7$"P33L\2RM,%..';[S?4XIMU=SWUR]S=2F6:3&YVZG Q_(5K
MKH^F7>GWTNG:C<2SV,(GE$UN(XW7(!"G<2#D\9ZUB1H\LBQQJ6=R%4#N:I6)
M:?4T3KVIO8)9/=%H$ "AD4LH!R &QG /;-21>)-8A-P4OGS/(9I"R*?G/5AD
M?*?<8J2_\+:OI^J)ISVK2W$G^K$9!W< GOQC/)-4;[3;W3)5CO;9X6==R;L$
M,/4$<&DN5C?.MRY#XDU>!YI$N\R3/YCN\:,V[^\"1P?I1#XAU6"W:".[*JQ8
MEMBE_FZX?&X9^M90I:=D3S2[BT444Q"4AI:2@#1T!0^M6X/8D_I7H4$2X.>M
M>>:')Y6K1/UQG^5=C_:,8(RQ5J\G&\OM5?L-2BGJ2:B?(!).5(XK)MKTL&7!
M.#Q3KZY:Y<8)*BHHU1#VR:X)K70YYR;G>.QJP7BA-K_+[TVXUJ*W;",#CKFJ
M$CDP\')]!69+9S7+C (/N*3YK60YU:B5H'<VNL7)L;1[..,K,29-V<\>E='8
M3NTBB5<;CQDYKEO#T CTF.)\,T,GZ&NG63RE@R,G.:S3G&?O/0^\PJA/+Z=E
MK;7U':EI\M_NC:8QPG@[1\Q'MZ54BTX6,(ALXHXXP, ;!^I[ULMECP>*:5!K
M;DBW<N%1J-C&&E^=('N9"V/X1P*OI!'&A5%"C':BYNH;5<LV/2D2>-8?.FD"
M GN:344[&C<FKDSI_HC ^E849 9E"%\'-:,VKP[6"$84<ECUKBY_'VF6%U)%
M,&9\\+$I8_\ UJWC*,E9&3A):L[:TN(G3KCV-7E=,<&N*M-4AU>$W=ON0/\
MWAC%31ZM+9MB9]T9Z,.U0ZO(]44J//L]3JIW7:1FL*]V2AD.#2_VBL\6]6W
M^AK*GNB)P<_+WINHI$NDXE>-/(U"-MP 8%=I[UM!%CC Q@,PV^_K7/7-W$^U
MEDSL.3CGBNFTR16LP\SK(5&0<?=':MH*YCS.+(6?(P*:ARU1&0.Y9#\I/%2Q
MG%<SLV<[W+D8XJ0J,=:J&?;0+H&G=;")B@JUI+;=9M/^N@%4?-!&:L:7DZQ9
M_P#79:<4KJPF]#TBBBBO2.0^<*2G4E=#/$$K;M%M[OPT;-[^UMIEO/-Q<,1E
M=F,C />L6DI-%1=CI[?4;"*>VTY+H&WBM)X3=.I53)(#SCJ%' S3;2[LM(@T
MJ*2\AN'M[QY9?(RP12H (..<>U<U28J;%^T9M:>D&D:E+,VIVLHDMYE5X7).
M2IQGC@G-)HNJ6FG6.G&=@Q@U#S7CQDA=N-V/K6)BHR*M,GF:V.G?48K6[M$^
MT:*MF;Y)W-DK[S@_>;/3W[UB)>V_D>(1)."]U(K19_Y:8E!S^59S+4#)6B:#
MG9T$NJ6;^+M7NS=*UO-:21QR'.&/E@ ?G5ZXUJ&2!+ZP?1(W%FL#B='%RN%V
ME0.ASV^M<:8Z58_:DTC:-1F[X62/9J/VMHTL&M_+F:9BJY)^4%ADCGT!K:BN
MH[.^#W)TYK.ZLC;6DBEY(0 >CGANO4^]<O87UUIY<VT@42##HZ!U;Z@@BI+N
M\NM0=9+F0N4&% 4*J#T ' %+ENR_:)(Z$:HL$QAEN-,CCCLY8X18;MBENV3W
M-0:%JUEIUCIZW#H3'<2%E*D[ RX#$>F?2N=VTQA3Y"/:O<U]>NB-/BLHWT;R
M/-,H33@V<XZG/2HX)K270]+S=V\<ME=%Y8I"0Q4D<KQS6*XJLW6K4=#*534Z
M5)=-U'Q9J-Q>SQ21R%V@>=F$;M_#N(YVUMQZII\$NFJMU9HUO:SQO]E5A&K-
MT SR<^M<%&*N1+3<2%5:.ATN\6'18(HKN*"[6]\Q3)T4;<9/'2M.-]+M=6L;
MHO9QW&7-P;1F:'D'!YZ$^@KED6I@M)Q&JC2.DTZ^MFTB"V7^S%N+>=Y/].5L
M')R&4CO534]0%WHQB>>)[A[UY9$B!"D8&"!Z5CA<]!FC%+E5Q^U=K&AHLL"1
MW]K-,L#74/EI*^=JD'."1T!JQ966G007,<MQILUVK+L,SL8=F.<8 RU8^VC;
M1RB50Z+5M2LYH]86"Y1A.(0@0$!PHYP/04D5[9S6$=D;N.*273U@\Q\[48-G
M:Q[ BN=VTFVCD*]J[W.E@N[*R.DPM?PR_9H;A)&0DJI8' !QSUJ&UFLI[K0[
MYM2M[9+%426.0L'&">5 '(-<^5J,I1RA[5G16+:0LL=[YMAYZWC23M=[RRIN
MRIC4<'BJU[/9WNG7J1W4 >/47NE60D>:A'\/')XZ5AE*1HRIPRD'T(Q56%[3
M2UCJ]5U6.X%]=6#:.%O8Q&1L<73 X^4CIG(Z].*YB^T[[#JCV+W$;&-PC2KG
M:I[^_%1;#UP>.](5SSUI)6+YN;<Z.[O!%I$BZCJ5EJ5U&T;630DO(F#D[GP#
MMQQ@YJ6"2PD\3?VU%J6FK9W,HDN;>]3,B*2"R[2I![X(KE"M,*U-C52-.VNK
M2(>) )$1+J$K;KC&[]Z" !]!5"PU.&P-HW]FV[2V]PDWVC+>80K!L=<>W2JY
M45&R$CH<#O2)U.C^UV.BRZMJ-O?V]XU](GV:&+.\)YHD8N"/E("XQZU'=S:=
M:/X@OX-2M[C^UD:.VB3=YB"20.QD&/EV@8]STKFF2H6%"B1*3.K6Z%GX?O+'
M4-;L;^Q-N5M+6V)9Q+_ WW05 YSDUSNJ:<^DW[6<DJ2R(B,^P<*64-MY[C.#
M5,BCDG)))/<U25C*4KG:W5[I\FNZE.FHVPAU>R\F.4$Y@;:@Q(,94$J1WK(U
M62WM] T_24NX;N>":69Y("62,,% 0$@9Z9..*P13J%&P.=Q12TE+5$"T444
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M\PSV JO;:Q<6D5FD21_Z),TR$@\D@ @^W%.BU6VAN6N$T>UWA]\9\R3]V?\
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MW,",=,X!]ZHV-\]C([*B21R)LDCD'RNOH<4),'*-T:4.C6EW):2V\DZ6UP)
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M3GUS6M:^'Y;F*%OM2(]QG[.AC<^8!W) PN>V:2+0LP6TES?P6QN6*1HR,QW
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8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g391920g0930212923522.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g391920g0930212923522.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )1 E@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!H^^?H/ZT4#[Y^@_K10 ZBBHKB>.UMI;B4XCB0NQ]@,T-VU8TFW
M9%;4=3BT]%!1YKB3(B@B&7<CK@>@[FL33CK.NW$[:C]IT^U3&R*(&)F.?[Q&
M2,=>G:M'28BL,NL7[!;BX3>2YXAB'(4'L,<GWJEI^K0V6@W,\=_+J[Q29.%(
M8;L #!S@=3FN.4N:2<W9:NW^?4]&G#DA*-.-Y72OYOMT7:[WW1<D\.:(9E$L
M&97SMWSN6/TRV:R[MGMEN6\.W=U-/:2*D]JQ:1%'/0,,YR.Q]:IZSX=U74]>
M74+4>7'*(V5F?:T. .HZ@@C/%='!J=G%-J;R6QLUMG'FS.@42^ASW]OJ/6HL
MI2:Y>7S[FS<H1C+G]H[*ZW2U6C6OIIK<9I&NM>LEM?6LEE>LNY8Y%($@'4KG
M^7\ZV:RY18^(]+S;W&Y0VZ.9.&BD'0^H(_K4ND7KWMCF<!;F%S#.HZ!UZ_@>
M#^-=-.35HMW[/N<-:$7><8\MGJNW]?A\R_6=?Z_HVEW"6^H:M8VDSC*1SW"(
MS#IP">:T:\\EL[[3]0\3ZGI2Z9K^G7;-]MM)9RDT<B+M:(-M96 &?E.W!K8Y
M3T,$$9!R#4$U[:6\\,$]S#%--GRHW<!GP,G:#UP/2N TC5VUFYT31O#]U=:/
MI+:5]L1@JR3$;MJQYE#C"]^">F#BLZUUJZUS6_!MU>!#<17-_;NZ#"R&,%=X
M'OC.*=@/4+2\M;^V6YL[F&X@;(62%PZG'!P1Q1;7EK>"0VMS#.(G,<GE.&V.
M.JG'0CTKRWPUKNJ7\'AG1;>[73A>_;)Y[BUMXE8K&Y 1%*% 23DG:>GOFNC^
M&Z/'::^DDJRN-9N,NHP&Z=J -Z7Q9X<@NVM)M?TN.Y1]C1/=QAPWH1G.?:M'
M[=:?;OL7VJ'[7Y?F>1Y@W[,XW;>N,]Z\C9-5N/#?CZVM[2S>Q>^N?.FDN&$J
M# W%8]FUB!R,NO/I5Q?$ATRYMKZP7[7;P>%OM,)FMT\Z0@C&Y@-P'JH;'\Z+
M"/5Z*X*SU36].U'0$N-5.I#6+61WCEBC189 @<%"B@A.<$,6/3GUIZ3XDUFR
M.=;NM074/LDDYLY[2)K>Y(3?_H\T78>C,QP>G>E89Z0S!5+,0% R2>U0V=[:
MZA:I=65S#<V\@RDL+AU;Z$<&N-T*ZURZL-&U6XU^WF74;9I9[*5(U7E=P$&%
MW';WW,W%<YH?B?5Y=+\-Z39Q7"O>6]Q<2OIL5M%)A)-H5!)B,#G)XSTQW-.P
M'KE%>:MKGBN,>%K.\N!9W-[J,]K.^V&1I8E5MK-M)57XYVG 8=,<4P^*=<M[
M34-,^W&6Y375TN/4)84W)&X5MQ"@)N&<#C&<9!I6 ]-HKS[7=9USPU:7$":J
MFIO-?6]M Y$0N8!)][>,)'G@[<@#D9S1]N\:1Z?K$$4,^]# +.6^EM!<?.<.
M,1GR\@<KN R3@YHL!Z#17+>$-5EOWOH)[_4)9H2I:UU.S6&X@SGJ4 1U.,@J
M/Q-=30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH :/OGZ#^M% ^^?H/ZT4 .HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]YJ#>9K&FF2TF& #).#M0X''S94_C75Z+%>PZ)91ZC<&XO1"OGRE0-SXYX
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M(M-#L]4M%D<VETTZ1E%8DA9%(SQGJ,UW]% '&ZEH.L70\)&00SSV&H"XO7B
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M#>HWWPZT_2X$0:C9K;2B-W&UGB*L5STYP1FI-7L]:U^PT.:72_LEQ;ZG%//
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M:+F'SU;8@1USD=>HX%1W6CZQHOB74-3TG3K;4[74BDDUO)(L;QRJ NX%N""
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M-]:WLT"O<VN[R9"3E-PP?S%,#S*__P"1%^)'_7Y<?^@+6]>_\C9X&_ZX3_\
MHI:Z=_#^E26=_:/9H;?4&9[I,G$I88)//L.E3/I5C)<V=RUNIFLE*V[9/[L$
M8./PH \RU".YET?XF):AC(;U<A.I7RH]V/\ @.:Z3Q3=Z1)\+;L120/;R6.V
MW1".6*_(% [YQ756NEV5G/>36]NJ27DGF7!Y/F-@+DY]@!6;!X,\.VU^M[#I
M,"SJV]3R55O4+G:#]!0(Y=[5Y/'G@9;]-]Q%I=PS;NT@6/GZ]:TM0^3XO:*5
MX,FE7(?'\0#IC-=1+IMG-J=OJ,D"M>6Z/'%*2<JK8W#\<"B33;.75(=2>!3>
M01M%'+DY56P2/3G I#,+XC_\DX\0?]>3_P JS-:N]%;X13*KPFU?3@D,:D9+
M[<* /[V['XUO^,M,NM9\&ZOIMD@>YN;9HXU9@ 6/N:BM?!VAK):WD^EP&]B1
M26Y(#@#)VYVY]\4 <S%:O)X^\&+?+NGAT65F#=G'EC\^:U-2_P"2N:%_V"[K
M_P!"CKJ)--LY=4AU)X%-Y!&T4<N3E5;!(].<"B33;.75(=2>!3>01M%'+DY5
M6P2/3G H \QO#+8V^J> XB5>]U)5MAGD6TV7<CV 605T6KW#Q>,-.T;2H+&V
MO(; NM[=J3Y<60NQ!W/KR*ZB71M.FUF'5Y+2-M0@C,4<YSN53U'I4>K^'M)U
MWRO[2LHYVB/[MB2K+]""#3 XSPK+.?BMKL=QJ,5]*NFP"22&+RUW!VXQDY(!
MZY[U?\$N1IGB*"-U%R-4N]J9Y!)XXKI;#P_I.F7 N+&QB@E$7D[DR/DSG'OS
MSGK21^'=)BUI]8CLD34''SS*2-W&.1G!..^* //?!JZO+X#A0:_I=O"D;I=1
M3V>61\G>'.\9.<\XKN/!EI#8^#M+MK>[^UP) /+GV[=Z]1QVXHN_!OAV^OVO
M;G2H'N'.7;D!S_M*#@_B*VT18T5$4*BC"JHP *0'"Z3-8Q?%WQ&)FC6Z:TMO
M++\$K@Y /Y5%:M'-X[\83V)5K0:;$DS)]TS@/G\=N,UI?\(E'?\ BS7+O5;*
M*:QNHX! 2WS;D4AL8Y7K706&BZ;I>GM86-G'!:MG=&@^]GKD]2?>F!YSI>H?
M9_ _@.RBM;62\ND7[//=Y\N!E0DM[G' %6_,O$^*^@17VK6U[<?9+G<MO!Y8
MC! X)W'.<?I7:3>&-%GT:#2)=/B>PMP!#"<_N\=,'.1^=-L_"VB:?+;RVNG1
M12V[,T;@G<"PP223D\>N:!'/?#^6*WC\00WLD::BNJSM<[R Q4G*$^VW&*R/
M$DFFGPAI\_A\I;:6NM*T\DD3-&#O.7*D\IOP?2NXU/PKH>LW(N;_ $Z*:8#:
M9,E21Z'!&1]:O_V=9?V?_9_V6'['L\OR-@V;?3% SB=4L+V\OM$_M7Q)IS[+
MZ.6V6"TVN[C)P#N. 1G-6?"$4?\ PG'C>;8OF&]@7=CG'DJ<5NZ9X3T'1[G[
M38:;%%, 0KY+%?\ =R3C\*O6NFV=E=W=U;P+'->.)+AP3F1@ H)_  4 <7X*
MM8$\$:\JQ(%DO]0##'4"1P/T%<Y%)=_\(M\-YENXK>,+M,]Q'YD:R&/";AD>
MX'/6O5K32K&QM)K6VMUC@F=Y)$!.&9R2Q_$DU$-!TK^Q4T8V,3:=&@C6W8;E
M"CIUH Y5M/NYO&.A3ZGXAL9KFW:5X8;>VV-(I0A@3N/'(/X5/X MXDN/$\ZH
M!++K,P=NY Q@5OZ5X:T;1)&DTZPCAD88+Y+-CTRQ)Q[5;LM.M-.\_P"R0+%]
MHE::7!/S.>IH \R9,?"CQO#&ORI=7P50.@W9X_6O1;"]M8O#]M=27$2V\=LC
MO(6&U1M')-2V^DV%I;W-O#:HL-S(\DR=0[-]XG/K56T\+Z+8Z9<Z;;6")97.
M1-"69E8$8QR>!]*0&G;W$-U;QW%O(LL,BAD=#D,#T(KC-?/AK7?%0T'6[1X+
MR&$36EX9/++@]0C YR.X-=C:6D%A:0VEK$L5O"@2.-1PJCH*J:MH6E:[ L.J
M6,-TBG*^8O*_0]10!PJPR^$_&6A6&D:[=ZA:ZA*\=S97,WG&- I/F!NH /%1
M^$AKA?7(H=:T^TN$U.<SQ7%KODY;*DG<,C;C''2NWT?PMH>@.TFF:;#;R,,&
M0 LQ'IN.32:EX4T+6+L7=]IL4MP!@R9*EAZ'!&1]:8CSO4K,6'P^A:SU2"YM
M3KHFGN%@/E(#)\WRY^X']\5N:Q87]]+HXU3Q-IQ1;Z*6W$%IM=W!S@'<< C(
M-=PNG62:?]@6UA%GLV>1L&S;Z8Z5G:;X1T'2+H7-CID,4P^Z^2VW_=R3M_"B
MX%S6EN'T+4%M,_:&MY!%C^]M./UKF/"UWI$?PMM!+) EO'8[;A'(X8+\X8'O
MG-=K6%/X,\.W-^U[-I,#3LV]CR%9O4KG:3]12&<%9K/:^'_AM+?;HUCO?F:3
MC8K1R! <^Q KH]=O;:;XF>%;:*9'E1+EV53G:"G&:ZO4=+L=6L6LK^UCGMFQ
MF-QQQTQZ?A5.Q\+:)ILL$MII\44D#,T;@DL"1@\DY/''-,# \%P1_P#"8>-;
MC8/-.HHF[N!Y2'%=)XB_Y%G5/^O27_T U8M--L[&XN[BV@6.6[D\V=@3\[8
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M_P#?UO\ &CV'F'UU=CZ:\Q/[Z_G1YB?WU_.OF3^TK[_G]N/^_K?XT?VE??\
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MW^-)_:5]_P _MQ_W];_&CV'F'UU=CZ;\Q/[Z_G1YB?WU_.OF3^TK[_G]N/\
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M8_\ GFG_ 'R*SG'E=CHI5/:*]AWF)_?7\Z/,3^^OYTGE1_\ /-/^^11Y4?\
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MKN48Y(ZYKJ(+^U\ZUU WJ"WBLO(>SR=Q;85(QTP2<YI+.>R\_3K][Z%%AL3
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MO(P51[FF5TWP_P!-_M3QKI\17*1OYS_1>?YXI-V5RHQYI)'T-I%DFFZ19V2
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MJ":A:+*N PX=?0U=KT$TU=',U8****8B*+_63_[X_P#05J6HHO\ 63_[X_\
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MS:W'A>_L)+R&WF>\AE3S2<%55P?YBM"UU/3XO+TL72F)--N;47+#"F24EO\
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MG+P\#W7M75AIV]UF-6/5&[111788$47^LG_WQ_Z"M2U%%_K)_P#?'_H*U+0
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MN%:94SE0QP#[\D53LK.XU"\BM+6,R32L%11ZUT.X0>';NQN+FSD\Q$6V%O\
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MVFE:Z&UAMH=(M+A[ 7,DUP\3%B> -N ,=^34\]C9Z;Q]D%YYEY)#\Q/RJI
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M]W';!4E2?[[ 9 *?6L>?6]^I7UWY&/M5J;?;N^[E%7/Z536TN)&=4MY&9/O
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M%%_K)_\ ?'_H*U+447^LG_WQ_P"@K4M #1]\_0?UHH'WS]!_6B@!U<O\0?\
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M^^/_ $%:EH :/OGZ#^M% ^^?H/ZT4 .KE_B#_P BA<_[\?\ Z$*ZBN7^(/\
MR*%S_OQ_^A"JA\2,ZO\ #EZ'CE%%%=AXX45<TO3Y=5U*"QA95DF)"EN@P"?Z
M59ET*YBTNYOR\?EV]P;=E!.2P[TFTAJ+:NC)HJQ9VDM_>PVL(S)*X5<^]6]9
MT2YT6^6UG9'+J&1T/# U+:O8%%M7,LT5MZAX8O\ 3M2M+.;83=%1%(,[22<8
M_"J%[IL]EJLNG$"2:.3R_D_B/;'YU-T-Q:W*5%=.?!=P@\E]0L4O"N[[,7^;
MIG&?6LG2-&N-8U'[' R1LH+.[GA0/6IN4Z<D[6,VBM3^P[H>(!HS%5N#+Y63
MT^OTJQ'X6U!_$#:,^R.X +!FSM8 9R*+H%"78PC25NZ9X9N=0M6O);B"TM58
MIYLQP&;T'K2S^%;FVU&"VGN[9(9T+Q71?]VP'OZUF[#Y)6O8YYA3"*ZO4_!L
MNF61N9=3LC^[,B(&.7'M7+D5<):DR@X[D9II.*<1435V0=S"0C28J(RFAZCK
M>*T.:3=QQ<FF'FEQDT\+2E9%P38P*<U,@I52I56L[FO**IQ3MU)BD-4C-W0N
M^D\RHF)S3,U:B9NI9ECS*7S/>JN:7-'(+VC+)DIC2<57+D5&SFI<2U,E>2H2
MV33"V:5:I*P2=R04\4P4\51DQU+FFTM,D=124M2RD,85$XJ<\U&PK.2-XLJ,
M*94SBHCUK%FZ8TTE*:2I&-HI:2@8E)2U-:6D]_=Q6MM&9)I6"HH[F@"YH.AW
M?B'5HM/LTRSG+N>B+W)KZ1T'0[7P_I,-A9IA$'S-W=NY-97@GP?!X5TH(=LE
M[, 9Y<=_[H]A75#I7-4GS,]/#T>17>XE%+161TB44M% "8]J*6B@ HHHH 2E
MHHH **** "BBB@ HHHH **** (HO]9/_ +X_]!6I:BB_UD_^^/\ T%:EH :/
MOGZ#^M% ^^?H/ZT4 .KE_B#_ ,BA<_[\?_H0KJ*Y?X@_\BA<_P"_'_Z$*J'Q
M(SJ_PY>AXY11178>.;G@^1(O%FGO(ZH@=LLQP!\C5T4%L-5\-ZM907-NLS:D
MSCS) H(XYK@:,FHE&[N:0J<JM8[+0=.BT"_OK_49X6^QP_NQ#(&)9^./<#^=
M)JD^GZKX6MYK61Q)I\H0B=QO9&/Z@$_I7'9/K2>U)QN[L:JV7+;0]*N=:LY?
M%G]G7LJ-:$PRP2@Y$4@ [^AZ&N;U"^@M?B))>LP>".[#$KR" !FN9I#UJ>4<
MJSD>AKI-J?$-Q?7;6-UI]U-YB7#W&&0$] ,]><56B32M#TS5II9&VWERUO$M
MNXWK&I[?Y]*X7)QC)Q0<U/*/VJZ([^XGLK[Q'X>UR&4*LSB.8.PW*RYY:KN@
MZW9WOB"5+^5!<VDDOV>=F #QDGY2?;M7F5%#B-5VG>QV:P)XC\*6=E:74,=W
M92OOAD?;O!/WA53Q(8;#P]IFB_:8[BZ@=Y96C;*IG/RYKE\D'()'TI#4M$NI
M=6.H\83Q36>@B.17*V0#!6SCIUKE#3C24A3ES.Y&PJ)A4Y%1L*Z:<C&2*SK4
M)%6F%0D5V1EH<LHZC%'-2J*:*D2HDS:G&Q(JU*!3%IXK*^IK;0"*C85(::16
MD69317>HZF<5":V1RR5F%%%)5$C&J-JD-1FD6AE/6D%/%"138X4X4T4ZF9CJ
M*2B@0ZG9IE**0#J8PIV:0U+1I&1 XJ!Q5IA4#BL9(Z(L@I*<>*;69H(:2E-)
M2&"JSN$12S$X"J,DGTKWCX=>!5T"T&HW\8.I3+P#SY*^@]_6LOX:^ ?L836]
M5B_TAAFWA8?ZL?WC[_RKU(<5SU*E]$=^&H6]^08HI:::Q.T7-&:S[K5[*S<1
M22[I3_RS0;F_(5#_ &] !N:WNPOKY)J'5@M+FL:%22NHFM2U4M-0M;Y"UO,K
MXZ@'D?4=JM52:>J,Y1<79BT444Q!1110 4444 %%%% !1110 4444 %%%% $
M47^LG_WQ_P"@K4M11?ZR?_?'_H*U+0 T??/T']:*!]\_0?UHH =7+_$'_D4+
MG_?C_P#0A745R_Q!_P"10N?]^/\ ]"%5#XD9U?X<O0\<HHHKK/&-#1;*/4=7
M@M)=VQPY.SKPA;C\JN3:%YJVC6@:%YDD=H;AL% G?..A'MVK-TZ^?3;^.[C4
M,\88 'W4K_6BVU":WFDESYC/"\1+D]&&/ZU+N:)QM9EF'0KJ<9CEMRI8I&=Y
MQ*1_=X_GBH6TJX33A?.T:1DD!68[C@X/;U]ZL6>N2VMHEL8A(L3%HSYC*5SZ
MX/(^M1KJ[)IDMF($S*"K2;FY!;.=N<9]\=*6HTH6%ET>7SYE1HX4BC1F>:3@
M%@"!G'4\U8O/#TB:I=6]NZ+# R*9)FP-S+D#('/>H6UII7N//M8I8YTC#1L2
M!E!A3D<^OYU,?$L[W=U+)"A2X=7,:NR;648!!!ST[4G<:Y.I6AT.ZE#EY((-
MLY@/G/CY_3H:2XT=[;2S>2W$2N)W@: YW KC/MWJ.35)9(C&RKS<FYSD_>]/
MIQ4\FL+=+)'=VR/&]TUQE204+8W <]P!UI:A[I4TVR^WZC%;%]BMN+-CHH!8
M_H*O6EII6HZE9VMO]IC,LZQL'(.5/<'L?:J,=\UOJGVVV18BLA=$ R #GY?I
MCBKD>MQV]U;SVFG6\#13"8[2QW$=LD\#V%((M6U"/09OM-NI:*:&:1HPT4G1
ME&2I..#CZU##H=W<6BSIY?SH9$C+?.ZCJ0,8['OVIUGK4UG#!&D2,(;AK@9[
MEEVX^E/BU^9+".V:(,T49CC?S&&%YZ@'!QD]:EW&N2PFJ:7;Z?IVGR+,LL]S
M%YK%6X )(X&/;KGUJ6[TRVM-.BE-G=2,\"R&<2 ("P],?UK-N[U[N.T1E4"V
M@$*X[@$G)_.K4VK0W%G'%-8(TL<0B67S7' '!VYQ4,=XW(I]%NX(UD81LDA0
M1%6SYNX<;?7W]#2S>'[Z.2*-1%*99#%^[;A7 R020,<<YZ5)/KLTL,$2PQ1I
M;,C6X4?ZK;UQZY/)SWI\_B.=[F&>.%$>.0R,&=G#DC!&">!@G@5<9-;":A8H
M-HL[7"PQ36TQ:-Y T4F1A 2W:EL?#TMZ4,ES#;I):RW2,Y/(3((/''*G\*E7
M5DM[V&>UL((DC5U:,%B'##!R2<]#QZ4G]OE)[=DLX%AAMI+7R06PT;YSSG.?
MF/-=492MH9.,+E<Z+*VFP7,6QBPG8L),AUC*YP,>^?I20:'=RS"/,:8@6=V=
MB!&C=-W&<\CCWI8]=FA6P1((Q'9R2NJ<D.),;E/M@8IT'B*XBU*\NC&K+=KM
MDB#%0%!! !!R,8&*<G(<5#06#1[AM=BTF3:DSR*N[.1@C.?<8YJV;+3KNVNS
M8&=)+5=^9B")%S@G@<'D5FOJL[ZJNHQ_NYD=63!+;=N,=?I5RXUI9;>:*VL8
M+4W&//>,DE^<X&3P,\X%9ZFJ4367PY9'4[*S-Y&?,M?M,KAS@C9NPOR\?X?E
M6;/HS.]N+;:L<L#3F223Y0H=EW$X&!QZ5$NM3+?PW8C3=%;?9@.<%?+,>?K@
MTL6MR)';QO!')#%;&V:-LX="Q;G'0Y/;TJH\Q$N1HB70;F664+-;>5$%W3^8
M=GS=!D#.3@]NU13>'[RWCN9+AH(%@D,3>8_+-MW +@'.1TJ[!KYMO/BCM(TM
M9=N88W9<%00#N!SGDYJAJ&KRWMO)$\:JKW'G\$D@[=H'/;%;P<SEJ1IV\S*I
M*#336QRH#3#2TE,I !3A2"E%,&**=3:6@D6BDI:0"TM-I:!#J*2EI!<:PJ%A
M4YZ5&PK.2-X,JN*CJ=Q4)K!G0G<97JWPW^'_ )S1:WK$/R [K:!QU_VF'\JK
M_#OX?-?/%K&KQXM5.Z"!A_K/]H^W\Z]G50H"J, < "N:I4Z([\/A_M2%  Z"
MBEI#6!WA61J%W/<7@TVR<K(1NFE'_+-?\36J[;48^@S6'I/F2:3=7D!5KFY9
MY 2>_11^&!651O2*-Z,4DYOI^;(/#=A9VSW=Q&\SR-*8V>X&#QZ57A\3SZE?
MW6GVT*PR!6\J1^0"/6HM"LM3U.*XBUGSQ&DBNFX[6W#KT[5T4VCV4T<Z_9U1
MIE*NZ#:Q'U%<\(SE!<FB_,[:TZ4*LO:^\]->B_S,EO#3M=C4(KQH;QD&[RQ\
MA;'IZ5JZ5?/=Q.DZ;+J$[)4'KZCV-<]*-:L_$L,$'F_V?&% [KL YS[U>CU&
MVFUBPOK1SY5X'@<$8)*\@X_ C\:*<HQ>BMKJ35ISG%<SYM+IKIY/Y'2#I6+<
M^+="LYS#/J<*R*<$ DX_*G>*)KF'PMJ4EIN\]8&VE>H]2/?&:\V\)6_@^ZTX
MQZNX%^[')E<J,=MI'%=QYIZU:7MM?P">UG2:(]&0Y%,O]2L]-A\Z\N8X(_5V
MQFN4\(>'9] U"]FAOHI]+E4^6%;<1@\'TSC-<]IUA+\0/$M[=W\T@L+9MJ1J
MV..RC\LD^] '>V?BO1+^<0VVHPO(> I)7/TS6I<7,5K;O//(L<48W,S'@"N)
MUSX<Z8VGO)I4;VUU$I9,.2'QV.:H:;KD^K_#/5HKIB\]K"8RYZL,<9]^U CT
M&QU"TU*$S6=PD\8;:60Y&:6^U"TTV 3WDZ01E@H9S@9/:N/^%?\ R*\W_7T_
M_H*T[XI_\BI%_P!?:?\ H+4AG42:O81:<E_)=QK:/C;*3\ISTJJGBG0Y'VKJ
MEMD_[>*XC5_^2.:=_P!LO_0C3O#G@+2=:\+6MY*9X[J5"2ZOP#DCI3T$>EQR
MI+&'C=74]&4Y!I]>6>"[R]T'QA/X;N93)"Q95R> P&01]17J=(84444 11?Z
MR?\ WQ_Z"M2U%%_K)_\ ?'_H*U+0 T??/T']:*!]\_0?UHH =7+_ !!_Y%"Y
M_P!^/_T(5U%<O\0?^10N?]^/_P!"%5'XD9U?X<O0\<HI*6NL\<?##+<2K%#&
MTDC=%49)J8Z=>BX-N;6;S@NXIM.<>OTI^EW,%I?++<H[Q;&4JAP>01^(]JT[
MG7;9U ABD7%BUMD*%Y+DYP.V*EMEQBFM69']GWANFM1;2_:%&3'MY ]:?=Z;
M/9WT=FPS-(D;!1URX! ^O-7QK%O)&\$J2B.2RBMW=,;@R$'(]0<5#J&K)-K5
MO?VRR#R%AVB0Y)9 !D_B*F['RQL17>F):QR'[=;R2Q'$D:YR/H<8.*K36-W!
M"DTUO+'&_P!UV4@&KEY/I<GFSV\5SY\C;@DF-B'.3TY/XXJU>:W:R_;I(HIG
MEOG5I(YB"B8;=@8Z^G; XHN#BC-L+'[;YY,Z0QP1^8[N">,@=O<TW["\UT8+
M)C=_+G=$A_K5NTUD6KWDL4"0O+!Y2")?E!W Y(/T-,M=1C*WJ7GF;;L+NDA4
M!E*G/3@8/I[5+8[1LD47M;B(.9(9%\M@C[EQM8] ?RJ:+3+^9W2*TF=D;:P5
M<X/H:TY=9L[N.X@GCN%B;R3&RX+DQJ5^;/J#UJ*_UB*Y%T(4D437BW"Y(X 7
M&/KFBX<L2C:Z7>7DI2&WE;:X1R%.$/O3GTB]%S=0Q6\DWV:1HW9%)&5)!_E6
MM+KMC<W/FR1W,8CO7NH_*(^8-MX;/?CK[FG+X@L6EEDEMW#"[EN8F"!C\S9
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M -\?^@K4M11?ZR?_ 'Q_Z"M2T -'WS]!_6B@??/T']:* '5R_P 0?^1/N?\
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M?].O_?T_X4?\*VU[_IU_[^G_  KV"BESL?U6F>/_ /"MM>_Z=?\ OZ?\*/\
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M^>$GYK_C1YK_ //"3\U_QJ6B@"+S7_YX2?FO^-'FO_SPD_-?\:EHH B\U_\
MGA)^:_XT>:__ #PD_-?\:EHH B\U_P#GA)^:_P"-'FO_ ,\)/S7_ !J6B@"+
MS7_YX2?FO^-'FO\ \\)/S7_&I:* (O-<_P#+!Q]2/\:-C.09<8!R%'3\?6I:
M* "BBB@!H^^?H/ZT4#[Y^@_K10 ZBBJ]Y#)-!B.\EM-IW&2((3CT^=2,?A0!
M8HKGM)U*2WT\W^J:C+);74X2T\V-0P4G"D[%'WNO3@$4FMW%_9K<W)U1;4CY
M;*V1$;[0P'0@@L23QA2.*=A7.BHK#>XOK_55L([A[$16RSSM$J,Y9B0%&X$8
M&#GCTJSHE[/=V]Q%=,K7%I.UN[J,!\8PV.V01Q18+FG17-7NM74/B) C@:9!
M)';7'R@YDD!(.>HQ\@_X%3M0U:\L_%UI;^8/[/>-%E3:.'<L%;.,]5 Z]Z+!
M<Z.BN;.K7DGC>.RCE T]8W1TVCYI0H8G/7@,HKI*5AW"BL'7M0EM+ZQA>\;3
M[*7>9;P(I"L,;4)8%5SDG)';%.L]3DM[,O-=Q:FLDVRSDM2I>88S@XPF1@\@
M@8':G85S<HK'?Q';16K32VUVDB7"V[VY0&17;IT)!!R.03UJU8:I'?33VY@F
MMKF#!>&;;N /0_*2"#ST/:BP7+U%<WK-UJ%DL]P=26&8OBRL41&^T8QP01N)
M)/\ "1@8JS)->ZAK$UC!=R64=M"CR-$B,S.^<#Y@1@ >G.>M%@N;=%9NAWTU
M]8/]HV&X@F>"4H,!F4XSCMD8./>EU)=0EFM(+.1H(79O/N$569 !P &R.3QG
M!I#-&BN735K_ .RR6BW DN&U$V4-VR+]W&XL0!M+ ;ATQD=*G>[U/3[ZXT]9
M3?RO:-<6IF"*Q=2 4.T*".0>W>G85SH:*YQ9]4L-2M[5KQ]0EGM))6BD1$V.
MN,8V@8!)QSGZTMO/J=GJ.E17=\UQ)>J_GP-&BB(A=V5VC. <+R3UHL%SHJ**
MQ_$5]<6%E"\+M#$\ZI/<K'O,$?)+8.1V R00,YI#-BBN>M]6^QV][>OJL6JZ
M;"H82Q%&F1NZD( I'0CH?K5D^(K>);C[3:75L\-NUR$E5<R1CJ5PQY''!P>1
M3L*YL45D#7XV2#R[&\DEN 6BA"H'9!CY^6 5>1]X@\]*DMM=M+J2SCC67?<M
M(@5E ,;)]Y6YX(]LT6"YIT5@:EXBDMXHVL[*:?\ TX6DGW1@@X.,L.3V[>N*
MM:Y>W=GH<ES:Q.LWRY^3>T2DC<VT=2HR<#/2BP7-6BN>L-1"S2W":_;:CIL<
M)>=F:/S(2.0?W:@8(SP1GBKD&O023+'<6US9&2(RQ&Y"@2*.21M8XP,'!P?U
MHL%S5HK%77X[A1&L%U:FXA=[6>6-2LF!G( ;/3G# 9%)!K,D6G6;&UO;^1[9
M9I)8H408P.3E@,G^ZI)HL%S;HK*M-1-YK+)%+OM'LHYXQMQRS-SZ] *U:0PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :/OGZ#^M% ^^?H/ZT4 .
MJEK%M<7NCWEK:NB331-&C.2 ,C':KM% %*6&[M[&WAT];?=&41A-NV^6.#C'
M?'2J.H6FLS+>VL?V*YM;E<(;ABAA!&"-JJ0X[C)![5MT4[BL88TJ\T^YM[FP
M,-PZVJVTR7$ACWA?NN&"MSR>,=^O%6])L)=/M)O-=)+J>5IY2O"[V[#O@8 _
M"M&BBX6.73P@DVD7,=Y/,;ZY9Y9&BNI1$)"<@[<@$#CJ.U3S:)>WJ3-=R0">
M6QCAW(Q(696+;AP.,D&NAHHNPLCGM.T*[MKC3+B>6)YH1.]TP)^>23!RO'3Z
MXXQ6Q)8VTM]!>O&3<0*RQON(P&Z\=#T[U9HHN%C.OHM3%W#<6$D,D:J4DM9V
M**V>C!@I((QZ$8/:L.7PK/.9+N6*Q>=[P7)LG!:#[NP@G;G)'.[;U[5UM%%P
ML<E>Z?/8Z?;"*VTZTEDU*%TBMH\(O;#' W=.N!C/M6OIUA=+JEWJ=\(8YID2
M)8H7+JJ+DY+$#))8]JUJ*+A8P=1L=9NX+ZQS97%K<Y"2S,5>%3U&P+A\=0<C
MW]:D;3KZQO\ [7IX@G,D"0S)<2F/)3.UPP5N>2",>G-;5%%PL8=G;7VE?8K:
M/RYS<3RRWLA5A@MELKC@#) Y/2K&MQ:K<6JPZ68$WMB9WE,;!/1"%;!/KCC^
M6I11<+&"=)N9-*MX8[>ULY[*59;98YFD0X[,2JGD$@G!ZYYJ2.RU-[Z;4YDM
M5NUMS!;0+*S1C)R2S[0>2!T' '>MJBBX6,#2;/5[1YIKNVLY;J<$R7 NV)8@
M?*H7RQM0>F>.O)HTBRU>"^>ZU&WLY+B;B2X2Z8[%'140QC"_\"YZDFM^BBX6
M*UU8VUY);O/&6:WD$L1W$;6QC/'7KWJ+4H;^1(9-/G1)(I-S12_<F7H5) )7
MU!&>>QJ]12&<=K6FWGV35M4N5M[>66V2$10,9 <,#O9BJY/;&.G>KM[HVHZK
M)<37?V6)Q92VT"QR,P8OU9LJ,#@<#/?FNDHIW%8R+G3[N*^M+^R6"2:* V\D
M4SE%93@Y# '!!'ISGM5&/0]0M7M+V)K::\2XFGFC=V1#Y@P0K!2>,#MS[5TM
M%%PL<T-#U'^RF1WMGO!J'VT#>P0_/G;G!(XR,X-;%_%?3V %I.EM=J5?D;D8
MCDH>,[3TR,'^57:*+A8YJ\T"\UJ[::_6VL_]%DMQ]FD,I??W8E5X&,@>_45)
M)H]_JLL/]J?9XHX(9(P+:1G,C.NTL<J-N!GCGKUXKH:*+A8Q+:SUGRHK:>2U
MCMX86B)B8L9SMVJ2"OR#O@$UG2^&[UUMHY8K&\CCLDMPER[%(' P75-I#9XZ
M[3QUYKK**+A8Q-%TBZT^2![AX3Y=A%;'RR?O*3D\CIR*VZ**0PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH :/OGZ#^M% ^^?H/ZT4 .HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
2B@ HHHH :/OGZ#^M%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
